Substituted 3-(5-(4-hydroxypiperidin-4-YL)-1-oxoisoindolin-2-YL)piperidine-2,6-dione derivatives and uses thereof
Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds serve as potent HIF-1β degraders, addressing the need for effective treatments for HIF-1β-related diseases by reducing protein levels and modulating activity in cellular and subject models.
Patent Information
- Application Number
- PCT/US2026/027190
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
There is a need for novel and potent small molecule modulators of hypoxia inducible factor 1 beta (HIF-1β) to treat a range of diseases associated with HIF-1β activity, including cancers, cardiovascular diseases, autoimmune and inflammatory diseases, neurodegenerative diseases, and metabolic diseases, as existing treatments are inadequate.
Development of substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds that act as HIF-1β degraders, effectively reducing HIF-1β protein levels in cells and tissues, thereby modulating HIF-1β activity.
The compounds demonstrate HIF-1β degrader activity at or below 50 pM levels, providing therapeutic benefits in treating various HIF-1β-dependent diseases such as cancers, cardiovascular diseases, and inflammatory diseases, with potential applications in reducing HIF-1β protein levels in cellular and subject models.
Smart Images

Figure US2026027190_12112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No.: N2109-7025WO
[0002] SUBSTITUTED 3-(5-(4-HYDROXYPIPERIDIN-4-YL)-l-OXOISOINDOLIN-2-YL)PIPERIDINE- 2,6-DIONE DERIVATIVES AND USES THEREOF
[0003] CLAIM OF PRIORITY
[0004] The present disclosure claims priority to U. S. Application No. 63 / 801,676, filed May 7, 2025. The entire content of the foregoing application is incorporated by reference in its entirety.
[0005] FIELD OF THE DISCLOSURE
[0006] The present disclosure relates to substituted 3-(5-(4-hydroxypiperidin-4-yl)-l-oxoisoindolin-2-yl)piperidine-2, 6-dione compounds and compositions for modulation of hypoxia inducible factor 1 beta (HIF-lb) and their use for the treatment of HIF-lb-dependent diseases or disorders or where reduction of HIF-lb protein levels can ameliorate a disease or disorder.
[0007] BACKGROUND OF THE DISCLOSURE
[0008] The HIF transcription factors are master regulators of the cellular response to hypoxia. The HIF transcriptional regulator acts as a heterodimeric complex consisting of the constitutively expressed hypoxia inducible factor 1 beta (HIF-lb, also known as ARNT) and either of the two HIF-a isoforms, HIF-la or HIF -2a. HIF-lb is a key player in both the hypoxic-response pathway and the aryl hydrocarbon receptor (AHR) pathway. The first evidence provided that the HIF heterodimer not only activates the erythropoietin gene but is also part of a widespread oxygen-sensing and signal transduction mechanism was demonstrated when HIF activity was detected in various non-erythropoietin-producing cell lines cultured under hypoxic conditions (Wang and Semenza, Proc. Natl. Acad. Set. USA, 1993, 90, 4304-4308; Maxwell et al., Proc. Natl. Acad. Set. USA, 1993, 90, 2423-2427).
[0009] Oxygen supply to tissues is essential in maintaining mammalian cell function and physiology and a deficiency in oxygen supply to tissues is a characteristic of a number of conditions in which there is insufficient blood flow to provide adequate oxygenation. Examples of diseases affected by inadequate oxygen supply include ischemic disorders, cancer, and atherosclerosis. Activation of a signaling cascade occurs in response to this hypoxic environment in tissues which drives the induction or repression of the transcription of a multitude of genes implicated in events such as angiogenesis (neo -vascularization), glucose metabolism, and cell survival / death. A key to this hypoxic transcriptional response lies in the transcription factors, the hypoxia inducible factors (HIF).
[0010] It has been shown that both HIF-a isoforms are rapidly degraded under normoxic conditions due to the oxygen-dependent hydroxylation of specific proline residues that mark the proteins for proteasomal degradation (Jewell, et a., Faseb. J., 2001, 15, 1312-1314; Gorlach, et al., Biochim. BioPhase. Acta, 2000, 1493, 125-134) and that under hypoxic conditions this hydroxylation is reversed, and the protein is further stabilized by phosphorylation (Wang et al., Biochip. Biophys. Res. Commun, 1995, 216, 669-675).Attorney Docket No.: N2109-7025WO
[0011] Consequently, the HIF-a proteins are then translocated to the nucleus, where they interact with HIF-lb to form a heterodimeric transcription factor (Kallio et al., Embo J, 1998, 17, 6573-65, 86). The dimerization step has been shown in HIF-lb deficient cells to be an absolute requirement for the transcriptional activation of hypoxia response element genes (Wood et aL, J. Biol. Chem., 1996, 271, 15117-15123). As a result, there are categories of genes that are activated by the HIF dimer which include oxygen transport genes, such as erythropoietin (Semenza, et al., J. Biol. Chem., 1994, 269. 23757- 23763) and transferrin (Rolfs et al., J. Biol. Chem., 1997, 272, 20055-20062); as well as genes involved in angiogenesis, such as VEGF (Levy et aL, J. Biol. Chem., 1995, 270, 13333-13340); and genes involved in anaerobic metabolism, such as glucose transporter 1 (Ebert et al., J. Biol. Chem., 1995, 270, 29083-29089). It is thought that hypoxia-induced genes such as VEGF play a role in promoting angiogenesis and subsequent tumor growth (Harris, Nat. Rev. Cancer, 2002, 2, 38-47).
[0012] Cellular oxygen concentration precisely regulates HIF transcriptional activity. While changes in oxygen levels do not affect HIF-lb protein levels, the abundance of the HIF-a subunits is markedly increased upon exposure of cells to hypoxia, primarily due to stabilization of the alpha subunits (Safran and Kaelin, J. Clin. Invest., 2003, 111, 779-783). The HIF-2a / HIF-lb heterodimer protein, which contains the core recognition sequence 5’-TACGTG-3’, binds to the hypoxic response element and is found in the cis-regulatory regions of hypoxia-regulated genes (Ema, et al., Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 4273-4278; Hogenesch, et al., J. Biol. Chem., 1997, 272, 8581-8593). It has been shown that binding of tire heterodimer to the hypoxia-responsive element (HRE) induces gene expression (Wiesener, et al., Blood, 1998, 92, 2260-2268).
[0013] A range of other genes regulated by the dioxin response element (DRE) can also be activated by HIF dimers resulting in some of the toxic and carcinogenic effects associated with many of the AHR ligands, such as immunotoxicity, developmental and reproductive toxicity, disruption of endocrine pathways, wasting syndrome, and tumor promotion Safe Toxicol. Let., 2001. 120, 1-7). It has been demonstrated that the AHR / HIF-lb heterodimer directly associates with the estrogen receptors ER-a and ER-b and that this association results in the recruitment of unliganded estrogen receptor and coactivator p300 to estrogen-responsive gene promoters. This association has been shown to lead the activation of transcription and estrogenic effects and to give rise to the adverse estrogen-related actions of dioxin-type cnviromncntal contaminants (Ohtakc ct al., Nature, 2003, 423, 545-550).
[0014] In summary, HIF-lb plays an important role in both the hypoxia-induced and AHR signaling pathways, which have been linked to various forms of malignancies (Harris, Nat. Rev. Cancer, 2002, 2. 8-47; Safe Toxicol. Lett., 2001, 120, 1-7). The angiogenic promoting capabilities of HIF-lb also make it a potential therapeutic target for a variety of angiogenic disorders, such as arthritis, cardiovascular diseases, skin conditions, aberrant wound healing and ocular conditions (e.g., macular degeneration, diabeticAttorney Docket No.: N2109-7025WO
[0015] retinopathy, diabetic macular edema and retinopathy of prematurity). Reduction of HIF-lb levels with small molecule modulators therefore has the potential to be a treatment for a range of diseases, including cancers, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary' arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases and other HIF-related diseases. For this reason, there remains a considerable need for novel and potent small molecule modulators of HIF-lb.
[0016] SUMMARY OF THE DISCLOSURE
[0017] The compounds of the disclosure have use as therapeutic agents, particularly for cancers, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary disorders (e.g., pulmonary' arterial hypertension (PAH)), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases, and other HIF-lb-related diseases. In one aspect, the compounds of the disclosure have HIF-lb degrader activity. In some embodiments, the HIF-lb degrader activity is at or below the 50 pM level, and more preferably at or below the 10 pM level, when administered to a cell or subject. The compounds of the disclosure have usefulness in treating cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary' arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases, and other diseases for which such degrader activity would be beneficial.
[0018] A first aspect of the present disclosure relates to compounds of Formula (I):
[0019]
[0020] pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Xi is N or CR3; X2is N, N(O), or CR5; Ri is H, D, -C(O)Rn, -CH2OC(O)Rn, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(OR12)2, -CH2OP(O)(ORI2)2, -CH2OP(O)(OH)OR12, -CH2OP(O)(RI2)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(R12 )NHR12, -CH2OC(O)(CH2)q-C(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S); R2a, R2b, R2c, and R2d are each independently H, D, (Ci-Ce)alkyl, (C1-C6)deuteroalkyl, halogen, or -OH; or two of R2a, R2b, R2c, and R2d may be taken togetherAttorney Docket No.: N2109-7025WO
[0021] with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl, wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40; R is H, D, (Ci-Ce)alkyl, (C1-C6)deuteroalkyl, or halogen; or, R3may be taken together with one of R2a, R2b, R2C, and R2dwith the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3- C7) spirocarbocyclyl, wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40; R4aand R4bare each independently H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)deuteroalkoxy, (Ci-C6)haloalkoxy, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4-to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or -NR9R10; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; each R5 is independently H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-Cg)haloalkyl, (Ci-Cg)alkoxy, (Ci-Cg)deuteroalkoxy, (Ci-Cg)haloalkoxy, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; R6is H, D, (C1-C6)hydroxyalkyl, (C1-C6)halohydroxyalkyl, (Ci-Cg)aminoalkyl, (Ci-Cg)alkyl-O-(Ci-C6)hydroxyalkyl, -C(0)Rn, -CH20C(0)Rn, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORi2)2, -CH2OP(O)(OH)ORi2, or -CH2OP(O)(Ri2)2; R7a, R7b, R7c, and R7dare each independently H, D, (Ci-Cg)alkyl, (Ci-Cg)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Cg)alkoxy, (Ci-Cg)haloalkoxy, halogen, (Ci-C6)hydroxyalkyl, -CN, -OH, -O-(Ci -Cg)hydroxyalkyl, (Cg-C 10) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R21, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; or two of R7a, R7b, R7c, and R7dare taken together with the carbon atom(s) to which they are attached to form (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-C6)alkyl, (Ci-Cg)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-Cg)haloalkoxy, (Ci-Cg)hydroxyalkyl, halogen. -C(0)0Ri3, -C(0)RB, and -C(0)NRI3RI3; each R7eis independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, (C1-C6)hydroxyalkyl, -CN, -OH, -O-(C1-C6)hydroxyalkyl, (C6-C10) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with oneAttorney Docket No.: N2109-7025WO
[0022] or more R21, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22: or two R7etogether with the carbon atom(s) to which they are attached form a (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from H, D. (Ci-Ce)alkyl, (Ci-Ceidcutcroalkyl. (Ci-C6)haloalkyl. (Ci-Ce)alkoxy. (Ci-Ce)haloalkoxy, (Ci-Celhydroxyalkyl. halogen, -C(0)0Ri3, -C(0)Ri3, -C(0)NRi3 R13, and oxo; or one R7eis taken together with any one of R7a, R7b, R7c, and R?d and the atoms to which they are attached to form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; Rs is (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)hydroxyalkyl, (C’i-C„)halohydroxyalkyl. or (C3-C7)carbocyclyl, wherein alkyl, haloalkyl. hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SFs, -SRi4a, -NRuRw, -C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R; R9and R10are each independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, or (Ci-Ce)haloalkyl; Rn is independently at each occurrence H, (Ci-C6)alkoxy, -NH2, -N(H)(Ci-C6)alkyl, -N((Ci-C6)alkyl)2, (Ci -Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-Ce)alkoxy, (Ci-Ce)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2, and -CN, or (C6-C10)aryl optionally substituted with one or more substituents independently selected from (C1-C6)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2. and -CN: R12 is independently at each occurrence H, (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (C6-Cio)aryl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-C io)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-Cjhaloalkyl. halogen, -OH, -NH2, and -CN; R12'is independently at each occurrence H or (C1-C6)alkyl; R13is independently at each occurrence (C1-C6)alkyl or (C1-C6)haloalkyl; R13'is independently at each occurrence H, (C1-C6)alkyl or (C1-C6)haloalkyl; R14and R14'are each independently at each occurrence H or (C1-C6)alkyl; R14ais H, (C1-C6)alkyl or (C1-C6)haloalkyl; R15 and Ris’ are each independently at each occurrence H, D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR30R31, -SF5, -SRie, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatomsAttorney Docket No.: N2109-7025WO
[0023] selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C )haloalkvl. (Ci-C, (alkoxy. (Ci-C. (haloalkoxy. (Ci-C,. (hydroxyalk l. halogen, -OH, -NR35R36, -C(O)NR37R38, -C(0)Rs7, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19: or two R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S. wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more R17; two R15, when on adjacent atoms, together with tire atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R17; or two R15 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; or two Ri5’ when on the same carbon atom form C=(0); Rie is H, (Ci-Ce)alkyl or (Ci-Cejhaloalkyl: R17 is independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-Cejdeuteroalkyl, (Ci-Cejhaloalkyl, (Ci-Cjalkoxy. (Ci-Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NR14R14’, -NH2, -SF5, -SRis, or -CN; or two R17 when on the same carbon atom form C=(0); Ris is H, (Ci-Ce)alkyl, or (Ci-Cejhaloalkyl; each R19 is independently at each occurrence H, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, -OR42, -NR20R20’, -OC(O)OR42. -OC(0)NR20R2O. -CN, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S, (Ce-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R24; or two R19 when on the same carbon atom fonn C=(0); or two R19 together with tire atoms to which they are attached fonn a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; R20 and R20’ are each independently at each occurrence H, (Ci-Ce)alkyl, or (Ce-Cio)aryl, wherein the alkyl and aryl are each optionally substituted with one or more R 1; each R21is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, -CN, phenyl, 5- or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-Attorney Docket No.: N2109-7025WO
[0024] C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more Ri?; or two R?i, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15; each R22is independently at each occurrence (C1-C6)alkyl, (C1-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR26, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (Cs-Cyjcarbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or two R22together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; each R23is independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroary l, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17; or two R23together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; each R24is independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, (C1-C6)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR28, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17; R25, R26, R27, R28, and R29 are each independently at each occurrence H, (Ci-Cejalkyl, or (Ci-Cejhaloalkyl: R30 and R31 are each independently at each occurrence H, (Ci-Ce)alkyl, (Ci-Cejhaloalkyl. (Cs-C7)carbocyclyl, -C(0)Rs4, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more Rn; R30and R31are each independently at each occurrence H, (C1-C6)alkyl, (C1-C6)haloalkyl, (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17; R32, R33, and R34 are each independently at each occurrence H or (Ci-Cejalkyl; R35 and R36 are each independently at each occurrence H, (Ci-Cs)alkyl, or -C(O)R39; R37, R38, and R39 arc each independently at each occurrence H or (Ci-C6)alkyl; R40 is D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-Attorney Docket No.: N2109-7025WO
[0025] C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR30R31, -SRi6, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, or phenyl; each R41is independently at each occurrence D, halogen, -OH, (C3-C7)carbocyclyl, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl are optionally substituted with one or more Ri?: each R42 is independently at each occurrence H. (Ci-Ce)alkyl, Si((Ci-Ce)alkyl)3. -(CH2)o-2-(C3-C7)carbocyclyl, -(CH2)o-2-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S), -(CH2)o-2-(phenyl), or -(CH2)o-2-(5- or 6-membered hctcroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein each alkyl, carbocyclyl, heterocyclyl, phenyl, and heteroaryl is optionally substituted with one or more R17; n is 0, 1, or 2; o is 0, 1, or 2; p is 0, 1, 2, 3, or 4; q is 1, 2, or 3; and r is 0 or 1.
[0026] In one aspect of the disclosure, the hydrogens in the Compound of Formula (I) are present in the normal isotopic abundances. In a preferred aspect of the disclosure, the hydrogens are isotopically enriched in deuterium (D), as discussed in more detail concerning isotopes and isotopic enrichment below.
[0027] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmacally acceptable carrier or excipient. Tire pharmacal composition is useful in the treatment of HIF-lb-dependent diseases or disorders. Tire pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0028] In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmacally acceptable carrier or excipient for use in the treatment of an HIF-lb-dependent disease or disorder by reducing HIF-lb protein levels wherein reduction of HIF-lb protein levels treats the HIF-lb-dependent disease or disorder. The pharmaceutical composition is useful in the treatment of HIF-lb-dependent diseases or disorders. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.
[0029] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient. Tire pharmaceutical composition is useful in the treatment of diseases or disorders affected by the reduction of HIF-lb protein levels. The pharmaceutical composition may further comprise at least one additional pharmaceutical agent.Attorney Docket No.: N2109-7025WO
[0030] In another aspect, the present disclosure relates to a method of degrading HIF-lb, comprising administering to a patient in need thereof an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0031] Another aspect of the present disclosure relates to a method of modulating HIF-lb levels comprising administering to a patient in need thereof an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0032] In another aspect, the present disclosure relates to an in vitro method of reducing the proliferation of a cell, comprising contacting the cell with an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0033] Another aspect of the present disclosure relates to a method of treating a disease or disorder that is affected by the modulation of HIF-lb levels, comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary' arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma (RCC), von Hippel-Lindau disease (VHL), pulmonary arterial hypertension (PAH), glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (rnssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease.
[0034] In another aspect, the present disclosure relates to a method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, the cancer is VHL-deficient cancer. In another embodiment, the cancer is selected from renal cell carcinoma (RCC), glioblastoma, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or nonHodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (rnssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), and myeloid leukemia.
[0035] Another aspect of the present disclosure relates to a method for reducing HIF-lb levels, comprising administering to a subject in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.Attorney Docket No.: N2109-7025WO
[0036] In another aspect, the present disclosure relates to a method of treating von Hippel-Lindau (VHL) disease, comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0037] Another aspect of tire present disclosure relates to a method of treating a neoplastic condition, comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0038] In another aspect, the present disclosure relates to a method of treating renal cell carcinoma (RCC), comprising administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
[0039] The present disclosure provides degraders of HIF-lb that are therapeutic agents in the treatment of diseases such as cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary' arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases, in the treatment of diseases affected by the modulation of HIF-lb protein levels, and in the treatment HIF-Ib-dependent diseases or disorders.
[0040] In one embodiment, the disease or disorder that can be treated by the compounds of the present disclosure is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases, including but not limited to, renal cell carcinoma (RCC), von Hippel-Lindau disease (VHL), pulmonary' arterial hypertension (PAH), glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell ly mphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease.
[0041] The present disclosure provides agents with novel mechanisms of action toward HIF-lb proteins in the treatment of various types of diseases including cancer von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases, in the treatment of diseases affected by the modulation of HIF-lb protein levels, and in the treatment HIF-lb-dependent diseases or disorders. Ultimately the presentAttorney Docket No.: N2109-7025WO
[0042] disclosure provides the medical community with a novel pharmacological strategy for the treatment of diseases and disorders associated with HIF-lb proteins.
[0043] DETAILED DESCRIPTION OF THE DISCLOSURE
[0044] The present disclosure relates to compounds and compositions that are capable of modulating HIF-lb protein levels. Tire disclosure features methods of treating, preventing, or ameliorating a disease or disorder in which HIF-lb plays a role by administering to a patient in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. The methods of the present disclosure can be used in the treatment of a variety of HIF-lb-dependent diseases and disorders by modulating HIF-lb protein levels. Modulation of HIF-lb protein levels through degradation provides a novel approach to the treatment, prevention, or amelioration of diseases including, but not limited to, cancer and metastasis, and other HIF-lb-dependent diseases or disorders.
[0045] In one aspect, the compounds of the disclosure have use as therapeutic agents, particularly for cancers, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases and other HIF-lb-related diseases. In one aspect, the compounds of the disclosure have HIF-lb degradation activity, preferably having such activity at or below the 50 pM level, and more preferably having such activity at or below the 10 pM level. The compounds of the disclosure have usefulness in treating cancer and other diseases for which such degradation activity would be beneficial for the patient. In summary, the present disclosure provides novel HIF-lb degraders useful for the treatinent of cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, metabolic diseases, allergic and genetic diseases and other disease related to the modulation of HIF-lb-related diseases.
[0046] In a first aspect of the disclosure, the compounds of Formula (I) are described:Attorney Docket No.: N2109-7025WO
[0047]
[0048] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof, wherein Ri, R2a, R2b, R2c, R2d, Ra. in. Rs, Rs, R?a, R?b, R?c, R?d, R?e, Rs, Xi, X2, n, o, p, r and subvariables thereof are as defined herein.
[0049] The details of the disclosure are set forth in tire accompanying description below. Although methods and materials similar or equivalent to those described herein can be used in the practice or of the present disclosure, illustrative methods and materials are now described. Other features, objects, and advantages of the disclosure will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents and publications cited in this specification are incorporated herein by reference in their entireties.
[0050] Definition of Terms and Conventions Used
[0051] Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification and appended claims, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.
[0052] A. Chemical Nomenclature, Terms, and Conventions
[0053] In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, (Ci-Cio)alkyl means an alkyl group or radical having 1 to 10 carbon atoms. In general, for groups comprising two or more subgroups, the last named group is the radical attachment point, for example, "alkylaryl" means a monovalent radical of the formula alkyl -aryl-, while "arylalkyl" means a monovalent radical of the formula aryl-alkyl-. Furthermore, the use of a temi designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups. The articles "a" and "an" refer to one or more than one (e.g., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
[0054] Tire term "and / or" means cither "and" or "or" unless indicated otherwise.Attorney Docket No.: N2109-7025WO
[0055] The term "optionally substituted" means that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded other substituents (e.g., heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Tirus, the tenn "optionally substituted" means that a given chemical moiety has the potential to contain other functional groups but does not necessarily have any further functional groups. Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(Ci-Ce)alkyl, (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkyl, (Ci-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl. (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6)alkyl, -C(O)(Ci-C6)alkyl, -OC(O)O(Ci-C6)alkyl, -NH2,
[0056] -NH((Ci-C6)alkyl), -N((Ci-C6)alkyl)2. -NHC(O)(Ci-C6)alkyl, -C(O)NH(Ci-C6)alkyl, -S(O)2(Ci-C6)alkyl, -S(O)NH(Ci-C6)alkyl, and S(O)N((Ci-C6)alkyl)2. The substituents can themselves be optionally substituted. " Optionally substituted" as used herein also refers to substituted or unsubstituted whose meaning is described below.
[0057] The term "substituted" means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.
[0058] The term "unsubstituted" means that the specified group bears no substituents.
[0059] Unless otherwise specifically defined, "aryl" means a cyclic, aromatic hydrocarbon group having 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group are optionally joined at a single point (e.g, biphenyl), or fused (e.g., naphthyl). The aryl group is optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(Ci-Ce)alkyl, (Cl-C5)alkyl, -O-(C2-C5)alkenyl, -O-(C2-C6)alkynyl, (C2-C5)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C5)alkyl, -C(O)(Ci-C6)alkyl, -OC(O)O(Ci-C6) alkyl, NH2, NH((Ci-C6)alkyl), N((Ci-C6)alkyl)2, -S(O)2-(Ci-C6)alkyl,
[0060] -S(O)NH(Ci-C6)alkyl. and S(O)N((Ci-C6)alkyl)2. The substituents are themselves optionally substituted. Furthermore, when containing two fused rings, the aryl groups optionally have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tctrahydronaphthalcnyl, tctrahydrobcnzoannulcnyl, and the like.Attorney Docket No.: N2109-7025WO
[0061] Unless otherwise specifically defined, "heteroaryl" means a monovalent monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical, containing one or more ring heteroatoms selected from N, 0, or S, the remaining ring atoms being C. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, 0, or S. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to. furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno [3,2-b]thiophene, triazolyl, triazinyl, imidazo[l,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[l,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno [3, 2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl, benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl. thiochromanyl. tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b ][l,6]naphthyridinyl, thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[ 1,5 -a] pyridinyl, [l,2,4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[ l,2-a]pyrimidinyl, tetrahydropyrrolo[ l,2-a]pyrimidinyl, 3,4-dihydro-2H-lA2-pyrrolo [2.1-b] pyrimidine. dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, lH-pyrido[3,4-b][l,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1,5-naphthyridinyl, furo[3,2-b]pyridine, [l,2,4]triazolo[l,5-a]pyridinyl, benzo[l,2,3]triazolyl, imidazo[l,2a]pyrimidinyl, [l,2,4]triazolo[4,3-b]pyridazinyl, benzo[c] [l,2,5]thiadiazolyl, benzo[c] [l,2,5]oxadiazole, l,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo [1,5-b] [l,2]oxazinyl,4,5,6, 7-tetraliydropyrazolo [l,5-a]pyridinyl, thiazolo[5,4d]tliiazolyl, imidazo[2,l-b] [l,3,4]thiadiazolyl,thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two fused rings the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary' ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofiiran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3,4-dihydro-lH-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.
[0062] " Alkyl" means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. Examples of a (Ci -Ce)alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, tert-butyl, isopentyl, neopentyl, and isohexyl.
[0063] " Alkoxy" means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal " O" in the chain, e.g., -O(alkyl). Examples of alkoxy groups include, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.Attorney Docket No.: N2109-7025WO
[0064] " Alkenyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkenyl" group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted and may be straight or branched.
[0065] " Alkynyl" means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The "alkynyl" group contains at least one triple bond in the chain. Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.
[0066] " Alkylene" or "alkylenyl" means a divalent alkyl radical. Any of the above-mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a (Ci-Csjalkylene. An alkylene may further be a (Ci-CAalkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-. -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH-, and the like.
[0067] " Amino" means a substituent containing at least one nitrogen atom (e.g., NH2).
[0068] " Cyano" means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, i.e., C=N
[0069] " Cycloalkyl" or "carbocyclyl" means a monocyclic or polycyclic saturated or partially unsaturated non-aromatic carbon ring containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof. A (C3-Cs)cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. A cycloalkyl group can be fused (e.g.. decalin) or bridged (e.g., norbomane).
[0070] " Deuteroalkyl" means an alkyl group substituted with one or more deuterium (“D”). Examples of deuteroalkyl groups include -CDH3, -CD3, -CHD2, -CD2CH3, -CD2CD3, CH2CD3, -CHDCH3, -CD2CH2CD3, etc.
[0071] ’Halogen" or "halo" mean fluorine, chlorine, bromine, or iodine.
[0072] " Haloalkyl" means an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.
[0073] " Elaloalkoxy" means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.Attorney Docket No.: N2109-7025WO
[0074] ‘'Halohydroxyalkyl” means an alkyl group substituted with at least one halogen and at least one -OH group. Examples of halohydroxyalkyl groups include, but are not limited to, HO-C(H)F-, HO-CH(F)-CH2-, CF3-CH(OH)-CH2-, and CH3-CH(OH)-, etc.
[0075] " Heterocyclyl" or "heterocycloalkyl" means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, or sulfur (O, N. or S) and wherein there is not delocalized n electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. Examples of heterocycloalkyl rings include, but are not limited to, oxetanyl, azetadinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide. thiomorpholinyl S-dioxide. piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, 1,4-dioxanyl, dihydrofiiranyl, 1,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.
[0076] " Hydroxyalkyl" means an alkyl group substituted with one or more -OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2CH2-, and CH3-CH(OH)-.
[0077] " Spirocarbocyclyl " or "spirocycloalkyl" means carbogenic bicyclic ring systems with both rings connected through a single atom. The rings can be different in size and nature, or identical in size and nature. Examples include spiropentane, spirohexane, spiroheptane, spirooctane, spirononane, or spirodecane. One or both of the rings in a spirocycle can be fused to another ring carbocyclic, heterocyclic, aromatic, or heteroaromatic ring. A (C3-C12) spirocarbocyclyl is a spirocycle containing between 3 and 12 carbon atoms.
[0078] " Spiroheterocyclyl" or "spiroheterocycloalkyl" means a spirocycle wherein at least one of the rings is a heterocycle one or more of the carbon atoms can be substituted with a heteroatom (e.g, one or more of the carbon atoms can be substituted with a heteroatom in at least one of the rings). One or both of the rings in a spiroheterocyclyl can be fused to another ring, e.g., carbocyclic, heterocyclic, aromatic, or heteroaromatic ring.
[0079] B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions
[0080] " Prodrug" or "prodrug derivative" means a covalently-bonded derivative or carrier of the parent compound or active drug substance which undergoes at least some biotransformation prior to exhibiting its pharmacological effect(s). In general, such prodrugs have metabolically cleavable groups and are rapidly transformed in vivo to yield the parent compound, for example, by hydrolysis in blood, and generally include esters and amide analogs of the parent compounds. The prodrug is formulated with the objectives of improved chemical stability, improved patient acceptance and compliance, improved bioavailability,Attorney Docket No.: N2109-7025WO
[0081] prolonged duration of action, improved organ selectivity, improved formulation (e.g., increased aqueous solubility), and / or decreased side effects (e.g., toxicity). In general, prodrags themselves have weak or no biological activity and are stable under ordinary conditions. Prodrags can be readily prepared from the parent compounds using methods known in the art, such as those described in A Textbook of Drag Design and Development, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach, 1991, particularly Chapter 5: " Design and Applications of Prodrags": Design of Prodrags, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs: Topical and Ocular Drag Delivery, K. B. Sloan (ed.), Marcel Dekker, 1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, Academic Press, 1985, particularly pp. 309-396; Burger’s Medicinal Chemistry' and Drag Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995, particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as Novel Delivery Systems, T. Higuchi and V. Stella (eds ), Am. Chem. Soc., 1975; Bioreversible Carriers in Drag Design, E. B. Roche (ed.), Elsevier. 1987, each of which is incorporated herein by reference in their entireties.
[0082] " Pharmaceutically acceptable prodrag" as used herein means a prodrag of a compound of the disclosure which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible.
[0083] " Salt" means an ionic form of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound. Salts of the compounds of the present disclosure can be synthesized from tire parent compounds which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.
[0084] " Pharmaceutically acceptable salt" means a salt of a compound of the disclosure which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and tire like, commensurate with a reasonable benefit / risk ratio, generally water or oil-soluble or dispersible, and effective fortheir intended use. Tire term includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts. As the compounds of the present disclosure are useful in both free base and salt form, in practice, the use of the salt form amounts to use of the base fonn. Lists of suitable salts are found in, e.g., S. M. Birge et al., J. Pharm. Set., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety.
[0085] " Pharmaceutically-acceptable acid addition salt" means those salts which retain the biological effectiveness and properties of the free bases and which arc not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid,Attorney Docket No.: N2109-7025WO
[0086] sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2 -acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethane sulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalene sulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3 -phenylpropionic acid, picric acid, pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and the like.
[0087] " Pharmaceutically-acceptable base addition salt" means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N, N -dimethylaniline, N -methylpiperidine, N -methylmorpholine, dicyclohexylamine, dibenzylamine, N, N-dibenzylphenethylamine, 1 -ephenamine, N, N’ -dibenzylethylenediamine, polyamine resins, and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.
[0088] " Solvate" means a complex of variable stoichiometry formed by a solute, for example, a Compound of Formula (I)) and solvent, for example, water, ethanol, or acetic acid. This physical association may involve varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances, the solvate will be capable of isolation, for example, when one or more solvent molecules are incorporated in the cry stal lattice of the cry stalline solid. In general, such solvents selected for the purpose of the disclosure do not interfere with the biological activity of the solute. Solvates encompasses bothAttorney Docket No.: N2109-7025WO
[0089] solution-phase and isolatable solvates. Representative solvates include hydrates, ethanolates, methanolates, and the like.
[0090] " Hydrate" means a solvate wherein the solvent molecule(s) is / are water.
[0091] Tire compounds of the present disclosure as discussed below include the free base or acid thereof, their salts, solvates, and prodrugs and may include oxidized sulfur atoms or quatemized nitrogen atoms in their structure, although not explicitly stated or shown, particularly the pharmaceutically acceptable fonns thereof Such forms, particularly the pharmaceutically acceptable forms, are intended to be embraced by the appended claims.
[0092] C. Isomer Terms and Conventions
[0093] " Isomers" means compounds having the same number and kind of atoms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.
[0094] " Stereoisomer" or "optical isomer" mean a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the disclosure which may give rise to stereoisomerism, the disclosure contemplates stereoisomers and mixtures thereof. The compounds of the disclosure and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. As discussed in more detail below, individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recry stallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well known in the art.
[0095] “Enantiomers" means a pair of stereoisomers that are non-superimposable mirror images of each other.
[0096] " Diastereoisomers" or "diastereomers" mean optical isomers, which are not mirror images of each other.Attorney Docket No.: N2109-7025WO
[0097] " Racemic mixture" or "racemate" mean a mixture containing equal parts of individual enantiomers. " Non-racemic mixture" means a mixture containing unequal parts of individual enantiomers.
[0098] " Geometrical isomer" means a stable isomer, which results from restricted freedom of rotation about double bonds (e.g., cis-2 -butene and trans-2 -butene) or in a cyclic structure (e.g., cis-1,3-dichlorocyclobutane and trans- 1,3 -dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, cyclic structures, and the like may be present in the compounds of the disclosure, the disclosure contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these cyclic structures. Tire substituents and the isomers are designated using the cis / trans convention or using the E or Z system, wherein the temi " E" means higher order substituents on opposite sides of the double bond, and the term " Z" means higher order substituents on the same side of the double bond. A thorough discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions. Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, which is hereby incorporated by reference in its entirety. Several of the following examples represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of the E and Z isomers can be done by analytical methods such as x-ray cry stallography,1H NMR, and13C NMR.
[0099] Some of the compounds of the disclosure can exist in more than one tautomeric form. As mentioned above, the compounds of the disclosure include all such tautomers.
[0100] It is well known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound. Thus, for example, enantiomers often exhibit strikingly different biological activity including differences in pharmacokinetic properties, including metabolism, protein binding, and the like, and pharmacological properties, including the type of activity displayed, the degree of activity, toxicity, and the like. Thus, one skilled in the art will appreciate that one enantiomer may be more active or may exhibit beneficial effects when enriched relative to the other enantiomer or when separated from the other enantiomer. Additionally, one skilled in the art would know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the disclosure from this disclosure and the knowledge of the prior art.
[0101] Tirus, although the racemic form of drug may be used, it is often less effective than administering an equal amount of enantiomerically pure drug; indeed, in some cases, one enantiomer may be phannacologically inactive and would merely serve as a simple diluent. For example, although ibuprofen had been previously administered as a racemate, it has been shown that only the S -isomer of ibuprofen is effective as an anti-inflammatory agent (in the case of ibuprofen, however, although the R-isomer is it is converted in vivo to the S-isomer, thus, the rapidity of action of the racemic form of the drug is less than that of the pure S-isomcr). Furthermore, the pharmacological activities of enantiomers may have distinct biological activity. For example. S-penicillamine is a therapeutic agent for chronic arthritis, while inactive,Attorney Docket No.: N2109-7025WO
[0102] R-penicillamine is toxic. Indeed, some purified enantiomers have advantages over the racemates, as it has been reported that purified individual isomers have faster transdermal penetration rates compared to the racemic mixture. See U. S. Pat. Nos. 5,114,946 and 4,818,541.
[0103] Thus, if one enantiomer is pharmacologically more active, less toxic, or has a preferred disposition in the body than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way, the patient undergoing treatment would be exposed to a lower total dose of the drug and to a lower dose of an enantiomer that is possibly toxic or an inhibitor of the other enantiomer.
[0104] Preparation of pure enantiomers or mixtures of desired enantiomeric excess (ee) or enantiomeric purity are accomplished by one or more of the many methods of (a) separation or resolution of enantiomers, or (b) enantioselective synthesis known to those of skill in the art. or a combination thereof. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective host-guest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and nonenzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are disclosed generally in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T. E. Beesley and R. P. W. Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc., 2000. Furthermore, there are equally well-known methods for the quantitation of enantiomeric excess or purity, for example, GC, HPLC, CE, or NMR, and assignment of absolute configuration and conformation, for example, CD ORD, X-ray crystallography, or NMR.
[0105] In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or stereoisomers or racemic or non-racemic mixtures, of a chemical structure or compound is intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.
[0106] D. Pharmaceutical Administration and Treatment Terms and Conventions
[0107] A "patient" or "subject" is a mammal, e.g., a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, or nonhuman primate, such as a monkey, chimpanzee, baboon or. rhesus. In certain embodiments, the subject is a primate. In yet other embodiments, the subject is a human.
[0108] An "effective amount" or "therapeutically effective amount" when used in connection with a compound means an amount of a compound of the present disclosure that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein.Attorney Docket No.: N2109-7025WO
[0109] The terms "pharmaceutically effective amount" or "therapeutically effective amount" means an amount of a compound according to the disclosure which, when administered to a patient in need thereof, is sufficient to effect treatment for disease-states, conditions, or disorders for which the compounds have utility. Such an amount would be sufficient to elicit the biological or medical response of a tissue, system, or patient that is sought by a researcher or clinician. The amount of a compound of according to the disclosure which constitutes a therapeutically effective amount will vary depending on such factors as the compound and its biological activity, the composition used for administration, the time of administration, the route of administration, the rate of excretion of the compound, the duration of treatment, the type of disease-state or disorder being treated and its severity, drugs used in combination with or coincidentally with the compounds of the disclosure, and the age, body weight, general health, sex, and diet of the patient. Such a therapeutically effective amount can be determined routinely by one of ordinary skill in the art having regard to their own knowledge, the prior art, and this disclosure.
[0110] As used herein, the term "pharmaceutical composition" refers to a compound of the disclosure, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, together with at least one pharmaceutically acceptable carrier, in a form suitable for oral or parenteral administration.
[0111] " Carrier" encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject. A subject is "in need of’ a treatment if such subject would benefit biologically, medically, or in quality of life from such treatment (preferably, a human).
[0112] As used herein, the term "inhibit", "inhibition", or "inhibiting" refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
[0113] As used herein, the term "treat", "treating", or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient.
[0114] As used herein, the term "prevent", "preventing", or "prevention" of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
[0115] " Pharmaceutically acceptable" means that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a formulation, and / or the mammal being treated therewith.Attorney Docket No.: N2109-7025WO
[0116] " Disorder" means, and is used interchangeably with, the terms disease, condition, or illness, unless otherwise indicated.
[0117] " Administer", "administering", or "administration" means to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative or analog of the compound or pharmaceutically acceptable salt of the compound or composition to the subject, which can form an equivalent amount of active compound within the subject’s body.
[0118] " Prodrug" means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a disclosed compound. " Compounds of the present disclosure", "compounds of the disclosure", and equivalent expressions (unless specifically identified otherwise) refer to compounds of Formulae (I), (I’), (la), (laa). (Ib), (Ibb), (Ic), (le), (If), (Ih), (li), (Ij), (Ik), (Im), (Io), (Ip), (Iq). (Is), (lu). (Iw). and (ly), as herein described including the tautomers, the prodrugs, salts particularly the pharmaceutically acceptable salts, and the solvates and hydrates thereof, where the context so permits thereof, as well as all stereoisomers (including diastereoisomers and enantiomers), rotamers, tautomers, and isotopically labelled compounds (including deuterium substitutions), as well as inherently formed moieties (e.g., polymorphs, solvates and / or hydrates). For the purposes of this disclosure, solvates and hydrates are generally considered compositions. In general and preferably, the compounds of the disclosure and the formula designating the compounds of the disclosure are understood to only include stable compounds thereof and exclude unstable compounds, even if an unstable compound might be considered to be literally embraced by the compound formula. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative, and it is not intended to exclude other instances when the context so pennits.
[0119] " Stable compound" or "stable structure" means a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic or diagnostic agent. For example, a compound, which would have a "dangling valency" or is a carbanion is not a compound contemplated by the disclosure.
[0120] In a specific embodiment, the term "about" or "approximately" means within 20%, preferably within 10%. and more preferably within 5% of a given value or range.
[0121] The yield of each of the reactions described herein is expressed as a percentage of the theoretical yield.
[0122] " Simultaneously" or "simultaneous" when referring to a method of treating or a therapeutic use means with a combination of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate,Attorney Docket No.: N2109-7025WO
[0123] solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agent(s) means administration of the compound and the one or more second agent(s) by the same route and at the same time.
[0124] " Separately" or "separate" when referring to a method of treating or a therapeutic use means with a combination of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agent(s) means administration of the compound and the one or more second agent(s) by different routes and at approximately the same time.
[0125] By therapeutic administration "over a period of time" means, when referring to a method of treating or a therapeutic use with a combination of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and one or more second agent(s), administration of the compound and the one or more second agent(s) by the same or different routes and at different times. In some embodiments, the administration of the compound or the one or more second agent(s) occurs before the administration of the other begins. In this way, it is possible to administer a one of the active ingredients (i.e., a compound of the Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or one or more second agent(s)) for several months before administering the other active ingredient or ingredients. In this case, no simultaneous administration occurs. Another therapeutic administration over a period of time consists of the administration over time of the two or more active ingredients of the combination using different frequencies of administration for each of the active ingredients, whereby at certain time points in time simultaneous administration of all of the active ingredients takes place whereas at other time points in time only a part of the active ingredients of the combination may be administered (e.g., for example, a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and the one or more second agents the therapeutic administration over a period of time could be such that a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, is administered once a day and the one or more second agent(s) is administered once every four weeks).
[0126] The compounds can be administered simultaneously (as a single preparation or separate preparation), sequentially, separately, or over a period of time to the other drug therapy or treatment modality. In general, a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.
[0127] " HIF-lb-dependent disease or disorder" means any disease or disorder which is directly or indirectly affected by the modulation of HIF-lb protein levels.
[0128] The term ' von Hippel-Lindau disease” or “VHL disease” or “VHL syndrome” or “von Hippel-Lindau syndrome”, as used herein, refers to a rare disease caused by a mutation in the von Hippel-Lindau (VHL) tumor suppressor leading to an aberrant non-functional VHL protein and to an absence of VHL protein. VHL gene mutations associated with this condition either prevent the production of any VHLAttorney Docket No.: N2109-7025WO
[0129] protein or lead to the production of an abnormal version of the protein, with more than 370 inherited mutations in the VHL gene having been identified in people with von Hippel-Lindau disease (http: / / www.umd.be / VHL / ). VHL disease is characterized by the formation of multiple benign and malignant tumors and fluid-filled sacs (cysts) in many different parts of the body, including: retinal hemangioblastoma, CNS hemangioblastoma, clear cell renal cell carcinoma (CCRCC), pheochromocytoma, pancreatic islet tumor, endolymphatic sac tumors and cysts in testes and broad ligament.
[0130] " Colitis" is an inflammation of the colon. The colitis may be acute or chronic. As used herein, colitis includes ulcerative colitis, microscopic colitis, lymphocytic colitis, collagenous colitis, diversion colitis, chemical colitis, ischemic colitis, infectious colitis, pancolitis, left-sided colitis, extensive colitis, segmental colitis, microscopic colitis, radiation -induced colitis, medication-induced colitis and proctitis.
[0131] E. Compounds
[0132] The present disclosure relates to compounds or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, capable of modulating HIF-lb protein levels, which are useful for the treatment of diseases and disorders associated with modulation of HIF-lb protein levels. The disclosure further relates to compounds, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, which are useful for reducing or decreasing HIF-lb protein levels.
[0133] The present disclosure features compounds of Formula (I):
[0134]
[0135] pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein X1 is N or CR3; X2 is N, N(O), or CR5; R1 is H, D, -C(O)R11, -CH2OC(O)R11. -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(ORI2)2. -CH2OP(O)(OH)OR12, -CH2OP(O)(R12)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(RI2)NHRI2. -CH2OC(O)(CH2)q-C(O)OR12, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S); R2a, R2b, R2c, and R2d are each independently H, D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, halogen, or -OH; or two of R2a, R2b, R2c, and R2d may be taken together with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl, wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40; R3 is H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, or halogen; or, R3 may be taken together with one of R2a, R2b, R2c, and R2d with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl, wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40; R4a and R4b are each independently H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl. (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)deuteroalkoxy, (Ci-Ce)haloalkoxy. (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4-to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or -NR9R10; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; each R5is independently H, D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cs)deuteroalkoxy, (Ci-Ce)haloalkoxy, (C3-C7)carbocyclyl, O(C3-C7)carbocyclyl, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; R6 is H, D, (C1-C6)hydroxyalkyl, (C1-C6)halohydroxyalkyl, (C1-C6)aminoalkyl, (Ci-Ce)alkyl-O-(Ci-C6)hydroxyalkyl, -C(0)Rn, -CH20C(0)Rn, -CH2OC(O)NHRI2, -CH2OC(O)OR12, -P(O)(ORI2)2, -CH2OP(O)(OH)ORI2, or -CH2OP(O)(RI2)2; R7a, R7b, R7c, and R7d are each independently H, D, (Ci-Cs)alkyl, (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, halogen, (Ci-C6)hydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, (Ce-Cio) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; or two of R7a, R7b, R7c, and R7d are taken together with tire carbon atom(s) to which they are attached to form (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)RB, and -C(0)NRB R13; each R7e is independently at each occurrence D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy, halogen, (C1-C6)hydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, (Ce-Cio) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH. and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl arc optionally substituted with one or more R22; or two R7e together with the carbon atom(s) to which they are attached form a (C3-C7)carbocyclyl, (C3-Attorney Docket No.: N2109-7025WO
[0136] C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from H, D, (Ci-Ce)alkyl, (Ci-C. Jdciiteroalkyl. (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)RB, -C(O)NRi3’Ri3’. and oxo; or one R7e is taken together with any one of R7a, R7b, R7c, and R7d and the atoms to which they are attached to form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; R8 is (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)hydroxyalkyl, (C1-C6)halohydroxyalkyl, or (C3-C7)carbocyclyl, wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SF?, -SRi4a, -NR14R14’, -C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R15; R9 and Rio are each independently at each occurrence H, D, (Ci-Cs)alkyl, (Ci-Ce)deuteroalkyl, or (Ci-Ce)haloalkyl; R11 is independently at each occurrence H, (C1-C6)alkoxy, -NH2, -N(H)(C1-C6)alkyl, -N((C1-C6)alkyl)2, (C1-C6)alkyl optionally substituted with one or more substituents independently selected from (C6-C10)aryl, (C1-C6)alkoxy, (C1-C6)hydroxyalkyl, (C1-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Cs-Cio)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (C -C. )haloalkyl. halogen, -OH, -NH2, and -CN; R12 is independently at each occurrence H, (Ci-C6)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-Ce)alkoxy. (Ci-C6)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN; R12 is independently at each occurrence H or (Ci-Ce)alkyl; R13 is independently at each occurrence (Ci-C.,)alkyl or (Ci-Ce)haloalkyl; RI3is independently at each occurrence H, (Ci-C. )alkyl or (Ci-Ce)haloalkyl; u and R14’ are each independently at each occurrence H or (Ci-Ce)alkyl; Ri4a is H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl; R15 and RB are each independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-Celdeuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR30R3I, -SF5, -SR16, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-mcmbcrcd hcteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4Attorney Docket No.: N2109-7025WO
[0137] heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-C )alkoxy. (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH. -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SF5. -SR29, SO2NR30R31, -CN, and R19; or two R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl, hctcroar l. carbocyclyl, and heterocyclyl are optionally substituted with one or more R17; two R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R17; or two Ri together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; or two Ri5’ when on the same carbon atom form C=(0); R16 is H, (C1-C6)alkyl or (C1-C6)haloalkyl; R17 is independently at each occurrence H. D, (Ci-Cs)alkyl, (Ci-Cs)deuteroalkyl, (Ci-Cs)haloalkyl, (Ci-Csjalkoxy. (Ci-Cs)haloalkoxy. (Ci-Cs)hydroxyalkyl, halogen, -OH, -NR14R14’, -NH2, -SFs, -SRis, or -CN: or two R17 when on the same carbon atom form C=(0); Ris is H, (Ci-Csjalkyl, or (Ci-Cs)haloalkyl; each R19 is independently at each occurrence H, (Ci-Cs)alkoxy, (Ci-Cs)haloalkoxy, -OR42, -NR2oR2o’, -0C(0)0R+2, -OC(O)NR20R20', -CN, (C3-C?)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S, (Cs-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH. and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R24; or two R1 when on the same carbon atom form C=(0); or two R19 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; R20 and R20’ are each independently at each occurrence H, (Ci-Cs)alkyl, or (C'.-C i )aryl. wherein the alkyl and aryl are each optionally substituted with one or more R41; each R21 is independently at each occurrence (Ci-Cs)alkyl, (Ci-Cs)haloalkyl, (Ci-Cejalkoxy, (Ci-Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl,Attorney Docket No.: N2109-7025WO
[0138] and heterocyclyl are each optionally substituted with one or more R17; or two R21, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more Ris; each R22 is independently at each occurrence (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Cgjalkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NH2. -SF5, -SR26, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N. NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or two R22 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; each R23 is independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)haloalkyl, (C1-C6)alkoxy, (C1-C6)haloalkoxy. (Ci-Ce)hydroxyalkyl, halogen. -OH, -NH2, -SF5, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH. and S, (C3-C7)carbocyclyl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17; or two R23 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; each R24 is independently at each occurrence H, D, (C1-C6)alkyl, (C1-C6)haloalkyl. (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR28, -CN, phenyl.
[0139] 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17; R25, R26, R27, R28, and R29 are each independently at each occurrence H. (Ci-Cejalkyl, or (Ci-Ce)haloalkyl; R30 and R31 are each independently at each occurrence H, (C1-C6)alkyl, (C1-C6)haloalkyl. (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17; R30 and R31 are each independently at each occurrence H, (C1-C6)alkyl, (C1-C6)haloalkyl. (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered heteroaiy 1 comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17; R32, R33, and R34 are each independently at each occurrence H or (C1-C6)alkyl; R35 and R36 are each independently at each occurrence H, (C1-C6)alkyl, or -C(O)R39 R37, R38, and R39 are each independently at each occurrence H or (Ci-Ce)alkyl; R40 is D, (Ci-Ce)alkyl, (Ci-Cejdeuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NR30R31, -SRie, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, or phenyl; each R41 is independently at each occurrence D,Attorney Docket No.: N2109-7025WO
[0140] halogen, -OH, (C3-C7)carbocyclyl, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl are optionally substituted with one or more Rn; each R42 is independently at each occurrence H, (C1-C8)alkyl, Si((C1-C6)alkyl)3, -(CH2)0-2-(C3-C7)carbocyclyl. -(CH2)o-2-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), -(CH2)o-2-(phenyl). or -(CH2)o-2-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S), wherein each alkyl, carbocyclyl. heterocyclyl. phenyl, and heteroaryl is optionally substituted with one or more R17: n is 0, 1, or 2; o is 0, 1, or 2; p is 0, 1, 2, 3, or 4; q is 1, 2, or 3; and r is 0 or 1. In some embodiments, R3 is D, (Ci-Cejalkyl, (Ci-C6)deuteroalkyl, or halogen. In some embodiments, R2e is independently at each occurrence D, (C1-C6)alkyl, (C1-C6)deuteroalkyl. (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, halogen, (Ci-Celhydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, (Ce-Cw) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S. (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more Rig, the aryl and heteroaryl are optionally substituted with one or more R21, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22
[0141] In some embodiments, compounds of Formula (I) are compounds of Formula (I'):
[0142]
[0143] pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein X1 is N or CR3; X2 is N, N(O), or CR5; R1 is H, D, -C(O)R11, -CH2OC(O)R11. -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(ORI2)2. -CH2OP(O)(OH)OR12, -CH2OP(O)(R12)2, -CH2OC(O)CH2NHC(O)CH2NH2, -CH2OC(O)CH(RI2)NHRI2, -CH2OC(O)(CH2)q-C(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S); R2a, R2b, R2c, and R2d are each independently H, D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, halogen, or -OH, wherein two of R2a, R2b, R2c, and R2(J may be taken together with the carbon atom to which they are attached form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl optionally substituted with one or more R40; R3 is H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl, or halogen, wherein R3 may be taken together with one of R2a, R2b, R2c, and R2d with the carbon atom to which they are attached to form a (Cs-C7)carbocyclyl or (C3-C7)spirocarbocyclyl optionally substituted with one or more R40; R4a and R4b are each independently H, D, (C1-C6)alkyl, (C1-C6)deuteroalkyl. (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)deuteroalkoxy, (Ci-C6)haloalkoxy, (C3-Attorney Docket No.: N2109-7025WO
[0144] C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR R10: wherein each alkyl, deuteroalkyl, haloalky 1, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; each R5 is independently H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)deuteroalkoxy, (Ci-C6)haloalkoxy, (C3-C7)carbocyclyl, O(C3-C7)carbocyclyl. (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40; R> is H, D, (Ci-Ce)hydroxyalkyl, (Ci-C6)halohydroxyalkyl, (Ci-C6)aminoalkyl, (Ci-C6)alkyl-O-(Ci-C6)hydroxyalkyl, -C(O)R11, -CH2OC(O)R11, -CH2OC(O)NHR12, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(OH)OR12, or -CH2OP(O)(Ri2)2; R?a, R?n. R?c, and R?d are each independently H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-C )alkoxy. (Ci-Ce)haloalkoxy, halogen. (Ci-Cehrydroxyalkyl. -CN, -OH, -O-(Ci-C6)hydroxyalkyl, (Ce-Cio) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the ary l and heteroaryl are optionally substituted with one or more R21, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; or two of R7a. R?b. R?c. and R?d are taken together with the carbon atoms to which they are attached form (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -C(0)0RB, -C(0)Ri3, and -C(0)NRB RB’; each R7, is independently at each occurrence D, (C’i-C,)alkyl. (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy. halogen, (Ci-CelhydroxyalkyL -CN, -OH, -O-(Ci-C6)hydroxyalkyl, (Ce-C10) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the ary l and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocycly l are optionally substituted with one or more R22; or two R?e together with the carbon atom to which they are attached form a (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocycly l, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-C6)alkyl, (Ci-C6)dcutcroalkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)R, and -C(0)NRB RB’; one R7. is taken together with anyAttorney Docket No.: N2109-7025WO
[0145] one of R?a, RTB R?c, and R?d and the atoms to which they are attached form a (C-Cvicarbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; Rs is (Ci-Cejalkyl, (Ci-C6)haloalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)halohydroxyalkyl, or (C3-C7)carbocyclyl, wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D. (Ci-Ce)alkoxy. -SF5, -SRua, -NR14R14’. -C(O)NR32Rs3, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Cs-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R; R9 and Rio are each independently at each occurrence H. D, (Ci-C6)alkyl, (Ci-C )dcutcroalk l. or (Ci-Cejhaloalkyl; Rn is independently at each occurrence H. (Ci-Ce)alkoxy. -NH2, -N(H)(Ci-C6)alkyl.
[0146] -N((Ci-C6)alkyl)2, (Ci-C6)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-C6)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from
[0147] (Ci-C6)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (C -Celhaloalkyl. halogen, -OH, -NH2, and -CN; R12 is independently at each occurrence H, (Ci-C6)alkyl optionally substituted with one or more substituents independently selected from (C6-Cio)aryl, (Cj-C, (alkoxy. (Ci-C )hydroxyalkyl. (Ci-Ce (haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-C6)alkoxy, (Ci-Ce)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN; R12 is independently at each occurrence H or (C’i-C )alkyl: R3is independently at each occurrence (Ci-Ce)alkyl or (Ci-Ce)haloalkyl; RB is independently at each occurrence H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl; R]and R14’ are each independently at each occurrence H or (Ci-Ce)alkyl; Ri4a is H, (Ci-Ce)alkyl or (Ci-Ce (haloalkyl; R15 and Ris are each independently at each occurrence D, (Ci-C6)alkyl, (Ci-Ceidcutcroalkyl. (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR30R31, -SFs, -SR16, -CN, -C(O)NRs2R33, -C(0)0RS2, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroar l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-C. (haloalkoxy. (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19; or two R15,Attorney Docket No.: N2109-7025WO
[0148] when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered hcteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more Ri?: two Ri5’, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N. NH, and S. wherein the phenyl and heteroaryl are optionally substituted with one or more Ri?; or two Ris together with the atoms to which they are attached form a (Cg-Cyjcarbocycl l or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Rn; or two Ris when on the same carbon atom form C=(O); Rie is H, (Ci-C.jalkyl or (Ci-Cejhaloalkyl; Ri? is independently at each occurrence D, (C, -C.jalky 1. (Ci-Cgjdeuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Cejalkoxy, (Cj-C„)haloalkoxy. (Ci-Cejhydroxyalkyl. halogen, -OH. -NH2, -SFs, -SRis, or -CN; Rig is H, (Ci-Cejalkyl, or (Ci-Cejhaloalkyl; each R is independently at each occurrence (Ci-Cejalkoxy, (C 1 -Cejhaloalkoxy, -OR 2, -NR20R20, -CN, (Cs-Cyjcarbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Ce-Cio) aryl, or monocyclic or bicyclic 5-to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R24; or two R19 when on the same carbon atom fonn C=(0); or two R19 together with the atoms to which they are attached form a (Cs-Cvjcarbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; R20 and R20 are each independently at each occurrence H or (Ci-Cejalkyl, wherein the alkyl is optionally substituted with one or more R41; each R21 is independently at each occurrence (Ci-Cejalkyl, (Ci-Cejhaloalkyl, (Ci-Cejalkoxy, (Ci -Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; or two R21, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15: each R22 is independently at each occurrence (Ci-Cejalkyl, (Ci-C,)haloalkyl. (Ci-Cejalkoxy, (Ci -Cejhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR26, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or two R22 together with the atoms to which they arc attached form a (C3-C7)carbocyclyl or a 4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; each R23 is independently atAttorney Docket No.: N2109-7025WO
[0149] each occurrence D, (Ci-C6)alkyl, (Ci -Csjhaloalkyl, (Ci-Ce)alkoxy, (Ci -C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or two R23 together with the atoms to which they are attached fonn a (Cs-C jcarbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S: each R24 is independently at each occurrence D, (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR28, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; R25, R26, R27, R2S, and R29 are each independently at each occurrence H, (Ci-Ce)alkyl, or (Ci-Ce)haloalkyl; R30 and R31 are each independently at each occurrence H, (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17: Rso and R31 are each independently at each occurrence H, (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17; R32, R33, and R34 are each independently at each occurrence H or (Ci-Ce)alkyl; R35 and R36 are each independently at each occurrence H, (Ci-Ce)alkyl, or -C(O)R39i R37, Rss, and R39 are each independently at each occurrence H or (Ci-Ce)alkyl; R40 is D, (Ci-Ce)alkyl, (Ci-Ce euteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NR30R31, -SRie, -CN, -C(O)NR32Rs3, -C(O)OR32, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, or phenyl; each R41 is independently at each occurrence D, halogen, -OH, (C3-C7)carbocyclyl, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl are optionally substituted with one or more R17; each R42 is independently at each occurrence H, (Ci-Celalkyl, tris[(Ci -Cslalkyljsilyl, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein alkyl, phenyl, and heteroaryl are optionally substituted with one or more R17; n is 0, 1, or 2; o is 0, 1, or 2; p is 0, 1, 2, 3, or 4; q is 1, 2, or 3; and r is 0 or 1.
[0150] In one embodiment, the compounds of Formula (I) are compounds of Fonnula (la):Attorney Docket No.: N2109-7025WO
[0151]
[0152] (la), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In one embodiment, the compounds of Formula (I) are compounds of Formula (laa):
[0153]
[0154] (laa), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (lb):
[0155]
[0156] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (Ibb):
[0157]
[0158] (Ibb), or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (Ic):Attorney Docket No.: N2109-7025WO
[0159]
[0160] r pharmaceutically acceptable salts, hydrates, solvates. prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are
[0161]
[0162] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (1) are compounds of Formula (If):
[0163]
[0164] pharmacally acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (Ih):
[0165]
[0166] (Ih), or pharmacally acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, tire compounds of Formula (I) are compounds of Formula (li):Attorney Docket No.: N2109-7025WO
[0167]
[0168] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Fonnula (Ij):
[0169]
[0170] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Fonnula (Ik):
[0171]
[0172] r pharmaceutically acceptable salts, hydrates. solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (Im):
[0173]
[0174] solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (Io):Attorney Docket No.: N2109-7025WO
[0175]
[0176] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Fonnula (Ip):
[0177]
[0178] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Fonnula (Iq):
[0179]
[0180] r pharmaceutically acceptable salts, hydrates. solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Fonnula (I) are compounds of Formula (Is):
[0181]
[0182] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Fonnula (I) are compounds of Formula (lu):Attorney Docket No.: N2109-7025WO
[0183]
[0184] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Fonnula (Iw):
[0185]
[0186] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof. In another embodiment, the compounds of Formula (I) are compounds of Formula (ly):
[0187]
[0188] r pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, and tautomers thereof.
[0189] In some embodiments, Xi is N. In some embodiments, Xi is CR3.
[0190] In some embodiments, X2is N. In some embodiments, X2is CR5.
[0191] In some embodiments, Ri is H. In some embodiments, Ri is D. In some embodiments, Ri is -C(O)Rn. In some embodiments, Ri is -CH2OC(O)RH. In some embodiments, Ri is -CH2OC(O)NHRI2. In some embodiments, Ri is -CH2OC(O)ORi2. In some embodiments, Ri is -P(O)(ORi2)2. In some embodiments, Ri is -CH2OP(O)(ORi2)2. In some embodiments, Ri is -CH2OP(O)(OH)ORi2. In some embodiments, Ri is -CH2OP(O)(Ri2)2. In some embodiments, Ri is -CH2OC(O)CH2NHC-(O)CH2NH2. In some embodiments, Ri is -CH2OC(O)CH(RI2)NHRI2. In some embodiments. Ri is -CH2OC(O)(CH2)q-C(O)ORi2. In some embodiments, Ri is or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S).
[0192] In some embodiments, R2a, R2b, R2c, and R2CI are each H. In some embodiments, R2ais H. In some embodiments, R2ais D. In some embodiments, R2ais (Ci-Cs)alkyl. In some embodiments, R2ais (Ci-Attorney Docket No.: N2109-7025WO
[0193] C„)dcutcroalkyl. In some embodiments, R.2a is halogen. In some embodiments, R.2a is -OH. In some embodiments, R2b is H. In some embodiments, R2b is D. In some embodiments, R2b is (Ci-C6)alkyl. In some embodiments, R2b is (Ci-C6)deuteroalkyl. In some embodiments, R2b is halogen. In some embodiments, R2b is -OH. In some embodiments, R2Cis H. In some embodiments, R2Cis D. In some embodiments, R2c is (Ci-Ce)alkyl. In some embodiments, R2Cis (Ci-C6)deuteroalkyl. In some embodiments, R2Cis halogen. In some embodiments. R2Cis -OH. In some embodiments, R2d is H. In some embodiments, R d is D. In some embodiments, R2d is (Ci-Cs)alkyl. In some embodiments, R2d is (Ci-C6)deuteroalkyl. In some embodiments, R2d is halogen. In some embodiments, Rod is -OH.
[0194] In some embodiments, two of R;,. R2b, R2c, and R2d may be taken together with the carbon atom to which they are attached form a (C3-C7)carbocyclyl optionally substituted with one or more R40. In some embodiments, two of R2a, R2b. R2c, and R2d may be taken together with the carbon atom to which they are attached form a (Ci-Cvispirocarbocvclyl optionally substituted with one or more Rio.
[0195] In some embodiments, Rs is H. In some embodiments, Rs is D. In some embodiments, Rs is (Ci-Ce)alkyl. In some embodiments, Rs is (Ci-C6)deuteroalkyl. In some embodiments, Rs is halogen. In some embodiments, Rs may be taken together with one of R;,. Rsb. Roc, and Rod with tire carbon atom to which they are attached to fonu a (C3-C?)carbocyclyl optionally substituted with one or more R o. In some embodiments, Rs may be taken together with one of Ro,. Rob, Roc. and ROJ with the carbon atom to which they are attached to form a (C3-C7)spirocarbocyclyl optionally substituted with one or more R40.
[0196] In some embodiments. Ria is H. In some embodiments, Riais D. In some embodiments, Riais (Ci-Ce)alkyl optionally substituted with one or more R40. In some embodiments, Ria is (Ci-C6)deuteroalkyl optionally substituted with one or more Rio. In some embodiments, Ria is (Ci-C6)haloalkyl optionally substituted with one or more R40. In some embodiments, Ria is (Ci-C6)alkoxy optionally substituted with one or more Rio. In some embodiments, Rais (Ci-Ce)deuteroalkoxy optionally substituted with one or more R o. In some embodiments, Riais (Ci-C,.)haloalkoxy optionally substituted with one or more Ro. In some embodiments, Rais (C3-C7)carbocyclyl optionally substituted with one or more Ro. In some embodiments, Riais -O(C3-C7)carbocyclyl optionally substituted with one or more Rio. In some embodiments, Riais 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R o. In some embodiments, Rais halogen. In some embodiments, R ais -OH. In some embodiments, Rais -NR9R10.
[0197] In some embodiments, R b is H. In some embodiments, Rib is D. In some embodiments. R b is (Ci-Ce)alkyl optionally substituted with one or more Rio. In some embodiments, Rib is (Ci -C6)deuteroalkyl optionally substituted with one or more Rio. In some embodiments, Rib is (Ci-C,,)haloalkyl optionally substituted with one or more R o. In some embodiments, Rib is (Ci-C,)alkoxy optionally substituted with one or more Rio. In some embodiments, Rib is (Ci-Ce)deuteroalkoxy optionally substituted with one or moreAttorney Docket No.: N2109-7025WO
[0198] Rio. In some embodiments, R-h is (Ci -Ce)haloalkoxy optionally substituted with one or more Rio. In some embodiments, R4bis (C3-C?)carbocyclyl optionally substituted with one or more R40. In some embodiments, R4b is -O(C3-C?)carbocyclyl optionally substituted with one or more R40. In some embodiments, R4b is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R40. In some embodiments, Rio is halogen. In some embodiments. Rib is -OH. In some embodiments, Rib is -NR9R10.
[0199] In some embodiments. Ria and Rib are each independently H or (Ci-Ce)alkyl. In some embodiments, Ria and Rib are each independently -H or -CH3. In some embodiments, at least one of Ria and Rib is H. In some embodiments, Ria and Rib are each H.
[0200] In some embodiments, an instance of R5 is H. In some embodiments, an instance of R5 is D. In some embodiments, an instance of R5 is (Ci-Ce)alkyl optionally substituted with one or more R40. In some embodiments, an instance of R5 is (Cj-C,.)dcutcroalkyl optionally substituted with one or more Rio. In some embodiments, an instance of Rs is (C -C.)haloalkyl optionally substituted with one or more Rio. In some embodiments, an instance of Rs is (Ci-Ce)alkoxy optionally substituted with one or more Rio. In some embodiments, an instance of Rs is (Ci-Ce)deuteroalkoxy optionally substituted with one or more R40. In some embodiments, an instance of Rs is (Ci-C6)haloalkoxy optionally substituted with one or more R40. In some embodiments, an instance of Rs is (C3-C7)carbocyclyl optionally substituted with one or more R40. In some embodiments, an instance of Rs is O(C3-C7)carbocyclyl optionally substituted with one or more R40. In some embodiments, an instance of Rs is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R40. In some embodiments, an instance of Rs is halogen. In some embodiments, an instance of Rs is -OH. In some embodiments, an instance of Rs is -NR9R10. In some embodiments, Rs is independently in each instance H or halogen. In some embodiments. Rs is independently in each instance -H or -F. In some embodiments, Rs is independently -F.
[0201] In some embodiments. Re is H. In some embodiments, Re is D. In some embodiments, Re is (Ci-Ce)hydroxyalkyl. In some embodiments, Re is (Ci-Ce)halohydroxyalkyl. In some embodiments, Re is (Ci-Ce)aminoalkyl. In some embodiments, Re is (Ci-Ce)alkyl-O-(Ci-Ce)hydroxyalkyl. In some embodiments, Re is -C(0)Rn. In some embodiments, Re is -CH20C(0)Rn. In some embodiments, Re is -CH2OC(O)NHRi2. In some embodiments, Re is -CH2OC(O)ORi2. In some embodiments, Re is -P(O)(OR12)2. In some embodiments. Re is -CH2OP(O)(OH)ORi2. In some embodiments, Re is or -CH2OP(O)(RI2)2. In some embodiments, Re is H or (Ci-Ce)hydroxyalkyl. In some embodiments, Re is H or -CH2CH2OH. In some embodiments, Re is H. In some embodiments, Re is -CH2CH2OH.
[0202] In some embodiments, at least two of R?a, R?b, R?c, and R / d arc each H. In some embodiments, at least three of R?,. R?b. R?c. and R?d are each H. hi some embodiments, R?,. R?b, R?c. and R?d are each H. InAttorney Docket No.: N2109-7025WO
[0203] some embodiments, R?ais H. In some embodiments, R?ais D. In some embodiments, R?ais (Ci-Cs)alkyl optionally substituted with one or more Ri.. In some embodiments, R?ais (Ci-C6)deuteroalkyl. In some embodiments, R?ais (Ci-Ce)haloalkyl. In some embodiments, R?ais (Ci-Cg)alkoxy. In some embodiments, R?, is (Ci-Ce)haloalkoxy. In some embodiments, R?ais halogen. In some embodiments, R?< is (Ci-C6)hydroxyalkyl. In some embodiments, R?ais -CN. In some embodiments, R?ais -OH. In some embodiments. R?ais -O-(Ci-C6)hydroxyalkyl. In some embodiments, R?ais (Ce-Cio)aryl optionally substituted with one or more R21. In some embodiments, R?ais 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R21. In some embodiments, R?ais (C3-C?)carbocyclyl optionally substituted with one or more R22. In some embodiments, R?ais 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N. NH, and S, wherein heterocyclyl is optionally substituted with one or more R22.
[0204] In some embodiments,?b is H. In some embodiments, RTB is D. In some embodiments. R?h is (Ci -Ce)alkyl optionally substituted with one or more R19. In some embodiments, R?b is (Ci -C,.)dcutcroalkyl. In some embodiments, R?b is (Ci-C6)haloalkyl. In some embodiments, R?b is (Ci-Ce)alkoxy. In some embodiments, R?b is (Ci-Cs)haloalkoxy. In some embodiments, R?b is halogen. In some embodiments, RTI, is (Ci-Ce)hydroxy alkyl. In some embodiments, R?h is -CN. In some embodiments, R?b is -OH. In some embodiments, R?n is -O-(Ci-C6)hydroxyalkyl. In some embodiments, R?n is (Ce-Cic>)aryl optionally substituted with one or more R21. In some embodiments, R?n is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R21. In some embodiments, R?b is (C3-C7)carbocyclyl optionally substituted with one or more R22. In some embodiments, R?b is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R22.
[0205] In some embodiments, R?cis H. In some embodiments, R?cis D. In some embodiments, R?cis (Ci-Ce)alkyl optionally substituted with one or more R19. In some embodiments, R?cis (C -C„)dcutcroalkyl. In some embodiments, R?cis (Ci-Ce)haloalkyl. In some embodiments, R?c is (Ci-Ce)alkoxy. In some embodiments, R?cis (Ci-C6)haloalkoxy. In some embodiments, R?c is halogen. In some embodiments, R?cis (Ci-Cs)hydroxy alkyl. In some embodiments, R?cis -CN. In some embodiments, R?cis -OH. In some embodiments, R?c is -O-(Ci-C6)hydroxyalkyl. In some embodiments, R?c is (C.-Ci. Jaryl optionally substituted with one or more R21. In some embodiments, R?cis 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R21. In some embodiments, R?cis (C3-C7)carbocyclyl optionally substituted with one or more R22. In some embodiments, R?cis 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R22.Attorney Docket No.: N2109-7025WO
[0206] In some embodiments, R?d is H. In some embodiments, R?d is D. In some embodiments, R?d is (Ci-Ce)alkyl optionally substituted with one or more Ri.. In some embodiments, R?d is (Ci -Cejdeuteroalkyl. In some embodiments, R?d is (Ci-Ce)haloalkyl. In some embodiments, R?d is (Ci-Ce)alkoxy. In some embodiments, R?d is (Ci-C6)haloalkoxy. In some embodiments, R?d is halogen. In some embodiments, R?<i is (Ci-Cs)hydroxy alkyl. In some embodiments, R?d is -CN. In some embodiments, R? i is -OH. In some embodiments. R?d is -O-(Ci-C6)hydroxyalkyl. In some embodiments, R?d is (Ce-Cic aryl optionally substituted with one or more R21. In some embodiments, R?d is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein hetcroaryl is optionally substituted with one or more R21. In some embodiments, R?d is (C3-C?)carbocyclyl optionally substituted with one or more R22. In some embodiments, R?d is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N. NH, and S, wherein heterocyclyl is optionally substituted with one or more R22.
[0207] In some embodiments, two of R?a. R?b. R?c, and R?d are taken together with the carbon atoms to which they are attached form (C3-C?)carbocyclyl optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)Ri3, and -C(O)NRi3-Ri3-. In some embodiments, two of R?a, R 71- R?c. and R?d are taken together with the carbon atoms to which they are attached form (C3-C7)spirocarbocyclyl optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)Ri3, and -C(0)NRi3 R13. In some embodiments, two of R?a, R?b, R?c, and R?d are taken together with the carbon atoms to which they are attached form a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-C,)dcutcroalkyl. (Ci-C6)haloalkyl, (Ci-Ce)alkoxy. (Ci-C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)Ri3, and -C(0)NRi3 R13.
[0208] In some embodiments, an instance of R?eis D. In some embodiments, an instance of R?eis (Ci-Ce)alkyl optionally substituted with one or more R19. In some embodiments, an instance of R?eis (Ci-C6)deuteroalkyl. In some embodiments, an instance of R?eis (Ci-Cs)haloalkyl. In some embodiments, an instance of R?e is (Ci-C.)alkoxy. In some embodiments, an instance of R?eis (Ci-C6)haloalkoxy. In some embodiments, an instance of R?eis halogen. In some embodiments, an instance of R?eis (Ci-Ce)hydroxyalkyl. In some embodiments, an instance of R?eis -CN. In some embodiments, an instance of R?eis -OH. In some embodiments, an instance of R?eis -O-(Ci-C6)hydroxyalkyl. In some embodiments, an instance of R?eis (Cc-Cio)aryl optionally substituted with one or more R21. In some embodiments, an instance of R?e is 5- or 6-mcmbcrcd hetcroary l comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, wherein hetcroaryl is optionally substituted with one or more R21. In some embodiments, an instance ofAttorney Docket No.: N2109-7025WO
[0209] R?e is (C3-C7)carbocyclyl optionally substituted with one or more R22. In some embodiments, an instance of R?eis 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R22.
[0210] In some embodiments, each R? is selected from
[0211]
[0212]
[0213] . insome embodiments, R?eis RK19\ ^J19
[0214] R19' / '
[0215] R ' R
[0216] independently
[0217]
[0218] In some embodiments, R?eis independently19 l'i9 |n some embodiments,
[0219] R7eis independently
[0220]
[0221] . In some embodiments, R?eis independently
[0222]
[0223] some embodiments, R / e is independently
[0224]
[0225] In some embodiments, R / eis independently
[0226]
[0227] In some embodiments, each R7e
[0228]
[0229] embodiments, R?eis independently
[0230]
[0231] In some embodiments. R?eis independently
[0232]
[0233] . In some
[0234] embodiments, R?e is independently
[0235]
[0236] In some embodiments, two R?etogether with the carbon atom to which they are attached form a (C3-C7)carbocyclyl optionally substituted with one or more substituents independently selected from D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-C6)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(O)ORi3, -C(O)Ri3, and -C(0)NRi3 R13. In some embodiments, two?eAttorney Docket No.: N2109-7025WO
[0237] together with the carbon atom to which they are attached form a (Cb-Cb)spirocarbocyclyl optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Cc deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(O)RB, and -C(O)NRB RB. In some embodiments, two R?etogether with the carbon atom to which they are attached form a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH. and S, wherein the spiroheterocyclyl is optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, (Ci-C6)haloalkyl, (Ci -C6)alkoxy, (Ci-Celhaloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -C(O)ORis, -C(0)Ri3, and -C(0)NRi3 R13.
[0238] In some embodiments, one R?e is taken together w ith any one of R?a, R?b, R?c, and R?d and the atoms to which they are attached form a (C3-C?)carbocyclyl optionally substituted with one or more R22. In some embodiments, one R?eis taken together with any one of R?,. R?b. R?c. and R?d and the atoms to which they are attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N. NH, and S, wherein the heterocyclyl is optionally substituted w'ith one or more R22.
[0239] In some embodiments, R« is (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SF5, -SRwa, -NR14R14, -C(O)NR32R33, phenyl, 5- orbmembered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted w ith one or more R15. In some embodiments, Rs is (Ci-Cs)haloalkyl optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SF5, -SRi4a, -NR14RW, -C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more Ri 5. In some embodiments, Rs is (Ci-Ce)hydroxyalkyl optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SF5, -SRi4a, -NR14R14, -C(O)NRs2R33, phenyl, 5- orbmembered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R15. In some embodiments, Rs is (Ci-Ce)halohydroxyalkyl optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SFs, -SR 4- -NR14R14’, -C(O)NR32Rs3, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl areAttorney Docket No.: N2109-7025WO
[0240] optionally substituted with one or more Ris and the carbocyclyl and heterocyclyl are optionally substituted with one or more R15. In some embodiments, Rs is (C3-C7)carbocyclyl optionally substituted with one or more substituents independently selected from R3I, D, (Ci-Ce)alkoxy, -SF5, -SRua, -NRwRw, - C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R15’.
[0241] In some embodiments, Rs is selected from:
[0242]
[0243] of X3aand X3b is independently selected from 0, S, NH, and NR15; X is selected from 0, S, NH, and NR15; R is selected from D, (Ci-C )alkyl and (C3-C?)cycloalkyl, and is optionally substituted with one or more of D, hydroxy, halogen, alkoxy, imidazol-2-yl, and -C(O)NR32R33; and R15, R15, R32, and R33are as defined (R15)0-5
[0244] herein. In some embodiments, Rs is
[0245]
[0246] , wherein R15 is as defined herein. In some embodiments,
[0247] (R15)0-4 (Ri 5)0-4
[0248]
[0249] wherein Ris is as defined herein. In some embodiments,
[0250]
[0251] whereinAttorney Docket No.: N2109-7025WO
[0252] (R15)0-4
[0253] Ris is as defined herein. In some embodiments, Rs is C A wherein R15 is as defined herein. In some (R15)0-3
[0254] embodiments, Rs is
[0255]
[0256] , wherein X3ais selected from selected from 0, S, NH, and NR15,
[0257] (R15)0-3
[0258] \^X3b
[0259] and R15 is as defined herein. In some embodiments, Rs is N^^X^X, wherein X3bis selected from selected from 0, S, NH, and NR15, and R15 is as defined herein. In some embodiments, Rs is (R15)0-4
[0260]
[0261] wherein R15 is as defined herein. In some embodiments, Rs
[0262]
[0263] wherein X3bis selected from selected from 0, S, NH, and NR15, and R15 is as defined herein. In some
[0264] embodiments,
[0265]
[0266] , wherein X3bis selected from selected from O, S, NH, and NR15, and
[0267] R15 is as defined herein. In some embodiments,
[0268]
[0269] wherein X3ais selected from selected from 0, S, NH, and NR15, and R15 is as defined herein. In some embodiments, Rs is
[0270]
[0271] ?wherein X3bis selected from selected from 0. S, NH. and NR15, and R15 is as defined
[0272] herein. In some embodiments,
[0273]
[0274] wherein X3ais selected from selected from 0, S,
[0275] (R15)0-2
[0276] x
[0277] NH, and NR15, and R15 is as defined herein. In some embodiments, R is, wherein X3ais selected from selected from 0, S, NH, and NR15, and R15 is as defined herein. In some embodiments, RsAttorney Docket No.: N2109-7025WO
[0278]
[0279] wherein R15 is as defined herein. In some embodiments, Rs
[0280]
[0281] wherein R[5is as defined herein. In some embodiments,
[0282]
[0283] wherein X3b is selected from selected from 0, S, NH, and NR15, and R15 is as defined herein. In some embodiments, Rs is
[0284]
[0285] , wherein X3ais selected from selected from 0, S, NH, and NR15, and Ris is as defined
[0286] herein. In some embodiments,
[0287]
[0288] wherein X3ais selected from selected from 0, S,
[0289] NH, and NR15, and Ris is as defined herein. In some embodiments,
[0290]
[0291] wherein R15 is
[0292] as defined herein. In some embodiments, Rs is
[0293]
[0294] , wherein R15 is as defined herein. In some
[0295] embodiments, Rs is
[0296]
[0297] . wherein X4 is selected from 0, S, NH, and NRis1, 15 is as defined
[0298] herein. In some embodiments,
[0299]
[0300] wherein RJ5is as defined herein. In some (R15')O-3
[0301] embodiments, Rs
[0302]
[0303] , wherein Ris is as defined herein. In some embodiments, Rs is (R15')o-3
[0304]
[0305] , wherein R15 is as defined herein. In some embodiments. Rs isRwherein R is selectedAttorney Docket No.: N2109-7025WO
[0306] from D, (Ci-C alkyl and (Cs-Cvlcycloalkyl, and is optionally substituted with one or more of D, hydroxy, halogen, alkoxy, imidazol-2-yl, and -C’iOjNR Rss: and R32 and R33 are as defined herein. In some
[0307] embodiments,
[0308]
[0309] , wherein R is selected from D, (Ci-C5)alkyl and (C3-C7)cycloalkyl, and is optionally substituted with one or more ofD, hydroxy, halogen, alkoxy, imidazol-2-yl, and -C(O)NR R3s:
[0310] and Ris, R32, and R33 are as defined herein. In some embodiments,
[0311]
[0312] wherein R15 is as defined herein.
[0313] In some embodiments, Rs is selected from:
[0314]
[0315] Attorney Docket No.: N2109-7025WO
[0316]
[0317] Attorney Docket No.: N2109-7025WO
[0318]
[0319] Attorney Docket No.: N2109-7025WO
[0320]
[0321] Attorney Docket No.: N2109-7025WO
[0322]
[0323] Attorney Docket No.: N2109-7025WO
[0324]
[0325] Attorney Docket No.: N2109-7025WO
[0326]
[0327] Attorney Docket No.: N2109-7025WO
[0328]
[0329] Attorney Docket No.: N2109-7025WO
[0330]
[0331] Attorney Docket No.: N2109-7025WO
[0332]
[0333] In some embodiments, Rg is H. In some embodiments, Rg is D. In some embodiments, Rg is (Ci-Ce)alkyl. In some embodiments, Rg is (Ci-Cs)deuteroalkyl. In some embodiments. Rg is (Ci-Q haloalkyl.
[0334] In some embodiments, Rio is H. In some embodiments, Rio is D. In some embodiments. Rio is (Ci-C6)alkyl. In some embodiments, Rio is (Ci-C6)deuteroalkyl. In some embodiments, Rio is (Ci-C6)haloalkyl.
[0335] In some embodiments, Rn is H. In some embodiments, Rn is (Ci-C6)alkoxy. In some embodiments, Rn is -NH2. In some embodiments, Rn is -N(H)(Ci-Ce)alkyl. In some embodiments, Rn is -N((Ci-C6)alkyl)2. In some embodiments, Rn is (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-C6)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Ci o)aryl optionally substituted with one or more substituents independently selected from (Ci-C6)alkyl, (Ci-C6)alkoxy, (Ci -C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN.
[0336] In some embodiments, RI2is H. In some embodiments, RI2is (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-Ce)alkoxy, (Ci-Ce)hydroxyalkyl, (Ci-C’dhaloalkyl. halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from (Ci-C6)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2, and -CN.
[0337] In some embodiments, RI2is H. In some embodiments, RI2is (Ci-Cejalkyl.
[0338] In some embodiments, R13 is (Ci-Ce)alkyl. In some embodiments, R is (Ci-Ce)haloalkyl.Attorney Docket No.: N2109-7025WO
[0339] In some embodiments, R13 is H. In some embodiments, RB’ is (Ci-C6)alkyl. In some embodiments, RB’ is (Ci-C6)haloalkyl.
[0340] In some embodiments, Ru is H. In some embodiments, R is (Ci-Ce)alkyl.
[0341] In some embodiments, Rw is H. In some embodiments, R14 is (Ci-Ce)alkyl.
[0342] In some embodiments, Rwa is H. In some embodiments, Ri4a is (Ci-Ce)alkyl. In some embodiments, Ri4a is (Ci-C6)haloalkyl.
[0343] In some embodiments, RES is D. In some embodiments, R15 is (Ci-Ce)alkyl optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C.)haloalkoxy. (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR3? R3s, -C(O)Rs7, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, R15 is (Ci-Ce)deuteroalkyl optionally substituted with one or more substituents selected from (Ci-Cs)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-Celhaloalkoxy, (Ci-Ce)hydroxyalkyl, halogen. -OH. -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, RES is (Ci-C6)haloalkyl optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (C’i-C )haloalkyl. (Ci-C6)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, R15 is (Ci-Ce)alkoxy optionally substituted with one or more substituents selected from (Ci-Cg)alkyl, (Ci-Cslhaloalkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, RB is (Ci-Ce)haloalkoxy optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-C6)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, R15 is (Ci-C6)hydroxyalkyl optionally substituted with one or more substituents selected from (Ci-Cg)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen. -OH. -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, RB is halogen. In some embodiments, RB is -OH. In some embodiments, RB is -NR30R31. In some embodiments, RB is -SF5. In some embodiments, RB is -SRB. In some embodiments, RB is -CN. In some embodiments, RB is -C(O)NR32R33. In some embodiments, R is -C(O)OR32. In some embodiments, R is (C3-C7)carbocyclyl optionally substituted with one or more substituents selected from (Ci-Cs)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and Ri In some embodiments, RES is -O(C3-C7)carbocyclyl optionally substituted with one or more substituents selected from (Ci-Co)alkyl, (Ci-Ce)haloalkyl, (Ci-C6)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, R is phenyl optionally substituted with one or more substituentsAttorney Docket No.: N2109-7025WO
[0344] selected from (Ci-Csjalkyl, (Ci-Cfi)haloalkyl, (Ci-Cs)alkoxy, (Ci -C,)haloalkoxy. (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R3I, -CN, and R]9. In some embodiments, Ris is -O-phenyl optionally substituted with one or more substituents selected from (Ci-C6)alkyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29. SO2NR30R3I, -CN, and RI9. In some embodiments. Ris is monocyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-C6)alkoxy, (Ci-Cs)haloalkoxy. (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and RJ9. In some embodiments, Ris is bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S, wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (C’i-Cs)haloalkoxv. (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and RI9. In some embodiments, Ris is -O-(monocyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and R19. In some embodiments, Ris is -O-(bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein hctcroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Cg)alkoxy, (C’i-C )haloalkoxy. (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR3SR36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and Ris. In some embodiments, Ris is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S. wherein heterocyclyl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Cejhaloalkyl. (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C,.)hydroxyalk l. halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and RI9. In some embodiments, Ris is -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein heterocyclyl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Cs)hydroxy alkyl, halogen, -OH, -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R3I, -CN, and R]9.
[0345] In some embodiments, Ris is D. In some embodiments, Ris is (Ci-Ce)alkyl optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C )hydroxyalkyl. halogen, -OH, -NR3R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR3QR3I, -CN, and RI9. In some embodiments, Ris is (Ci-Cs)dcutcroalkyl optionally substituted with one or more substituents selected from (Ci-Cs)alkyl, (Ci-C6)haloalkyl, (Ci-Cs)alkoxy, (Ci-Attorney Docket No.: N2109-7025WO
[0346] C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37Rs8, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris is (Ci-C6)haloalkyl optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-C. Jhaloalkoxy. (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)RB7, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Rn is (Ci-Ce)alkoxy optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Cfi)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris is (Ci-Ce)haloalkoxy optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Rn is (Ci-C6)hydroxyalkyl optionally substituted with one or more substituents selected from (Ci-Cg)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Cslhydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris is halogen. In some embodiments, Ris is -OH. In some embodiments, Ris- is -NR30R31. In some embodiments, Ri is -SF5. In some embodiments, Ri is -SR,,. In some embodiments, Ris is -CN. In some embodiments, Ris is -C(O)NR32R33. In some embodiments, Ris is -C(O)OR32. In some embodiments. Ris- is (C3-C7)carbocyclyl optionally substituted with one or more substituents selected from (Ci-Cg)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R8, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris- is -O(C3-C7)carbocyclyl optionally substituted with one or more substituents selected from (Ci-Cg)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris is phenyl optionally substituted with one or more substituents selected from (Ci-C6)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci -Ce)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFs, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris- is -O-phenyl optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29. SO2NR30R31, -CN, and R1. In some embodiments, Ris is monocyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Cjalkyl. (Ci-Cgjhaloalkyl, (Ci-C )alkoxy. (Ci-Cgjhaloalkoxy, (Ci-Cjhydroxyalk l. halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SFS, -SR29, SO2NR30R31, -CN, and R19. In some embodiments, Ris is bicyclic 5- to 10-mcmbcrcd hctcroaryl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more substituents selected fromAttorney Docket No.: N2109-7025WO
[0347] (Ci-Cfi)alkyl, (Ci-Csjhaloalkyl, (Ci-Ce)alkoxy, (Ci-Csjhaloalkoxy, (Ci-Cfi)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R3I, -CN, and RI9. In some embodiments, Ris is -O-(monocyclic 5- to 10-membered hcteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Cg)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH. -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R3I, -CN, and R]9. In some embodiments, Ris is -O-(bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein heteroaryl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-C.)alkoxy. (Ci-Ce)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, - OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR3CR3I, -CN, and Ri9. In some embodiments, Ris is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH. and S, wherein heterocyclyl is optionally substituted with one or more substituents selected from (Ci -Cjalkyl. (Ci-Ce)haloalkyl, (Ci-C.)alkoxy. (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R3I, -CN, and RI9. In some embodiments, Ris is -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), wherein heterocyclyl is optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Cs)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38. -C(O)R37, -C(O)OR37, -SFS, -SR29. SO2NR30R3I, -CN, and R]9.
[0348] In some embodiments, two Rs. when on adjacent atoms, together with the atoms to which they are attached form a phenyl optionally substituted with one or more RI7. In some embodiments, two Ris, when on adjacent atoms, together with the atoms to which they are attached fonn a 5 - or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more RI7. In some embodiments, two Ris. when on adjacent atoms, together with the atoms to which they are attached form a (C3-C7)carbocyclyl optionally substituted with one or more RI7. In some embodiments, two Ris, when on adjacent atoms, together with the atoms to which they are attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more Rn.
[0349] In some embodiments, two Ri s. when on adjacent atoms, together with the atoms to which they are attached form a phenyl optionally substituted with one or more Rn. In some embodiments, two Ris. when on adjacent atoms, together with the atoms to which they are attached form a 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heteroaryl is optionally substituted with one or more Rn. In some embodiments, two Ris, when on adjacent atoms, together with the atoms to which they arc attached fonn a (C3-C7)carbocyclyl optionally substituted with one or more Rn. In some embodiments, two Ris, when on adjacent atoms, together with the atoms to which they areAttorney Docket No.: N2109-7025WO
[0350] attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R17.
[0351] In some embodiments, two Ris- when on the same carbon atom form C=(O).
[0352] In some embodiments, Ris is H. In some embodiments, Ris is (Ci-C6)alkyl. In some embodiments, Ri6 is (Ci-C6)haloalkyl.
[0353] In some embodiments, an instance of R17 is D. In some embodiments, an instance of R17 is (Ci-Ce)alkyl. In some embodiments, an instance of R17 is (Ci-Cs)deuteroalkyl. In some embodiments, an instance of R17 is (Ci-C6)haloalkyl. In some embodiments, an instance of R17 is (Ci-Cs)alkoxy. In some embodiments, an instance of R17 is (Ci-Cs)haloalkoxy. In some embodiments, an instance of R17 is (Ci-Cs)hydroxyalkyl. In some embodiments, an instance of R17 is halogen. In some embodiments, an instance of R17 is -OH. In some embodiments, an instance of R17 is -NH2. In some embodiments, an instance of R17 is -SF?. In some embodiments, an instance of R17 is -SRis. In some embodiments, an instance of R17 is -CN.
[0354] In some embodiments, two R17 when on the same carbon atom form C=(O).
[0355] In some embodiments, Rig is H. In some embodiments, Rig is (Ci-C6)alkyl. In some embodiments, Ris is (Ci-Ce)haloalkyl.
[0356] In some embodiments, an instance of R19 is (Ci-Cs)alkoxy. In some embodiments, an instance of R19 is (Ci-C6)haloalkoxy. In some embodiments, an instance of R19 is -OR42. In some embodiments, an instance of R19 is -NR20R20’. In some embodiments, an instance of R19 is -CN. In some embodiments, an instance of R19 is (C3-C7)carbocyclyl optionally substituted with one or more R23. In some embodiments, an instance of R19 is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R23. In some embodiments, an instance of R19 is (Cs-Cio) aryl optionally substituted with one or more R24. In some embodiments, an instance of R19 is monocyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R24. In some embodiments, an instance ofRig is bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R24.
[0357] In some embodiments, two R19 when on the same carbon atom form C=(0).
[0358] In some embodiments, two R19 together with tire atoms to which they are attached form a (C3-C7)carbocyclyl optionally substituted with one or more R17. In some embodiments, two R19 together with the atoms to which they are attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heterocyclyl is optionally substituted with one or more R17.
[0359] In some embodiments, an instance of R20 is H. In some embodiments, an instance of R20 is (Ci-C. Jalkyl optionally substituted with one or more R41.Attorney Docket No.: N2109-7025WO
[0360] In some embodiments, an instance of R20 is H. In some embodiments, an instance of R20 is (Ci-Ce)alkyl optionally substituted with one or more R41.
[0361] In some embodiments, an instance of R21 is (Ci-Ce)alkyl. In some embodiments, an instance of R21 is (Ci-C6)haloalkyl. In some embodiments, an instance of R21 is (Ci-Ce)alkoxy. In some embodiments, an instance of R21 is (Ci-Ce)haloalkoxy. In some embodiments, an instance of R21 is (Ci-C)hydroxyalkyl. In some embodiments, an instance of R21 is halogen. In some embodiments, an instance of R21 is -OH. In some embodiments, an instance of R21 is -NH2. In some embodiments, an instance of R21 is -SFs. In some embodiments, an instance of R21 is -SR25. In some embodiments, an instance of R21 is -CN. In some embodiments, an instance of R21 is phenyl. In some embodiments, an instance of R21 is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S. In some embodiments, an instance of R21 is (C3-C7)carbocyclyl. In some embodiments, an instance of R21 is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S.
[0362] In some embodiments, two R21, when on adjacent atoms, together with the atoms to which they are attached form a phenyl optionally substituted with one or more R15. In some embodiments, two R21, when on adjacent atoms, together with the atoms to which they are attached fonn a 5 - or 6-membered heteroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R15.
[0363] In some embodiments, an instance of R22 is (Cj-C. )alkyl. In some embodiments, an instance of R22 is (Ci-Cejhaloalkyd. In some embodiments, an instance of R22 is (Ci-Cejalkoxy. In some embodiments, an instance of R22 is (C-C )haloalkoxy. In some embodiments, an instance of R22 is (Ci-Ce)hydroxyalkyl. In some embodiments, an instance of R22 is halogen. In some embodiments, an instance of R22 is -OH. In some embodiments, an instance of R22 is -NH2. In some embodiments, an instance of R22 is -SF5. In some embodiments, an instance of R22 is -SR26. In some embodiments, an instance of R22 is -CN. In some embodiments, an instance of R22 is phenyl. In some embodiments, an instance of R22 is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S. In some embodiments, an instance of R22 is (C3-C7)carbocyclyl. In some embodiments, an instance of R22 is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S.
[0364] In some embodiments, two R22 together with tire atoms to which they are attached form a (C3-C7)carbocyclyl. In some embodiments, two R22 together with the atoms to which they are attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S.
[0365] In some embodiments, an instance of R23 is D. In some embodiments, an instance of R23 is (Ci-Cejalkyl. In some embodiments, an instance of R23 is (Ci-C. )haloalkyl, In some embodiments, an instance of R23 is (Ci-Ce)alkoxy. In some embodiments, an instance of R23 is (C -C )haloalkoxy. In some embodiments, an instance of R23 is (Ci-Cgjhydroxyalkyl. In some embodiments, an instance of R23 isAttorney Docket No.: N2109-7025WO
[0366] halogen. In some embodiments, an instance of R23 is -OH. In some embodiments, an instance of R22is -NH2. In some embodiments, an instance of R23 is -SFs. In some embodiments, an instance of R23 is -SR27. In some embodiments, an instance of R23 is -CN. In some embodiments, an instance of R23 is phenyl. In some embodiments, an instance of R23 is 5- or 6-membered hctcroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S. In some embodiments, an instance of R23 is (C3-C7)carbocyclyl. In some embodiments, an instance of R23 is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S.
[0367] In some embodiments, two R23 together with the atoms to which they are attached form a (C3-C7)carbocyclyl. In some embodiments, two R23 together with the atoms to which they are attached form a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S.
[0368] In some embodiments, an instance of R24 is D. In some embodiments, an instance of R24 is (Ci-Ce)alkyl. In some embodiments, an instance of R24 is (Ci-C. )haloalk\l, In some embodiments, an instance of R24 is (Ci-C6)alkoxy. In some embodiments, an instance of R24 is (Ci-Cejhaloalkoxy. In some embodiments, an instance of R24 is (Ci-Ce)hydroxyalkyl. In some embodiments, an instance of R24 is halogen. In some embodiments, an instance of R24 is -OH. In some embodiments, an instance of R2is -NH2. In some embodiments, an instance of R24 is -SF5. In some embodiments, an instance of R24 is -SR28. In some embodiments, an instance of R24 is -CN. In some embodiments, an instance of R24 is phenyl. In some embodiments, an instance of R24 is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S. In some embodiments, an instance of R24 is (C3-C7)carbocyclyl. In some embodiments, an instance of R2is 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S.
[0369] In some embodiments, an instance of R25 is H. In some embodiments, an instance of R25 is (Ci-Ce)alkyl. In some embodiments, an instance of R25 is (Ci-Celhaloalkyl.
[0370] In some embodiments, an instance of R2. is H. In some embodiments, an instance of R2e is (Ci-Ce)alkyl. In some embodiments, an instance of R26 is (Ci-Ce)haloalkyl.
[0371] In some embodiments, an instance of R27 is H. In some embodiments, an instance of R27 is (Ci-C.)alkyl. In some embodiments, an instance of R27 is (C’i-C. )haloalkyl.
[0372] In some embodiments, an instance of R2> is H. In some embodiments, an instance of R2s is (Ci-Ce)alkyl. In some embodiments, an instance of R2s is (Ci-C’„)haloalk l.
[0373] In some embodiments, an instance of R2g is H. In some embodiments, an instance of R2is (Ci-Ce)alkyl. In some embodiments, an instance of R29 is (Ci-Ce)haloalkyl.
[0374] In some embodiments, an instance of R30 is H. In some embodiments, an instance of R30 is (Ci-Ce)alkyl. In some embodiments, an instance of R30 is (Ci-C6)haloalkyl. In some embodiments, an instance of R30 is (C3-C7)carbocyclyl. In some embodiments, an instance of R30 is -C(O)R34. In some embodiments,Attorney Docket No.: N2109-7025WO
[0375] an instance of R30 is phenyl optionally substituted with one or more Ri 7. In some embodiments, an instance of R30 is or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R17.
[0376] In some embodiments, an instance of R31 is H. In some embodiments, an instance of R31 is (Ci-Ce)alkyl. In some embodiments, an instance of R31 is (C’i-C )haloalk l. In some embodiments, an instance of R31 is (C3-C7)carbocyclyl. In some embodiments, an instance of R31 is -C(O)R34. In some embodiments, an instance of R31 is phenyl optionally substituted with one or more R17. In some embodiments, an instance of R31 is or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R17.
[0377] In some embodiments, an instance of R32 is H. In some embodiments, an instance of R32 is (Ci-Ce)alkyl.
[0378] In some embodiments, an instance of R33 is H. In some embodiments, an instance of R33 is (Ci-Ce)alkyl.
[0379] In some embodiments, an instance of R34 is H. In some embodiments, an instance of R34 is (Ci-Ce)alkyl.
[0380] In some embodiments, an instance of R35 is H. In some embodiments, an instance of R35 is (Ci-Ce)alkyl. In some embodiments, an instance of R;o is -C(O)R39.
[0381] In some embodiments, an instance of R36 is H. In some embodiments, an instance of R36 is (Ci-Ce)alkyl. In some embodiments, an instance of Rseis -C(O)R39.
[0382] In some embodiments, an instance of Rs7is H. In some embodiments, an instance of R37is (Ci-Ce)alkyl.
[0383] In some embodiments, an instance of Rss is H. In some embodiments, an instance of R38 is (Ci-Ce)alkyl.
[0384] In some embodiments, an instance of RM is H. In some embodiments, an instance of R39 is (Ci-Ce)alkyl.
[0385] In some embodiments, R40 is D. In some embodiments, R40 is (Ci-Ce)alkyl. In some embodiments, R 0 is (Ci-Cs)deuteroalkyl. In some embodiments, R40 is (Ci-Ce)haloalkyl. In some embodiments, R 0 is (Cj-C )alkoxy. In some embodiments, R40 is (Ci-C6)haloalkoxy. In some embodiments, R40 is (Ci-Ce)hydroxyalkyl. In some embodiments, R40 is halogen. In some embodiments, R40 is -OH. In some embodiments, R40 is -NR30R31. In some embodiments, R40 is -SRie. In some embodiments, R40 is -CN. In some embodiments, R40 is -C(O)NR32Rs3 In some embodiments, R40 is -C(O)OR32. In some embodiments, R 0 is (C3-C7)carbocyclyl. In some embodiments, R40 is -O(C3-C7)carbocyclyl. In some embodiments, R40 is phenyl.Attorney Docket No.: N2109-7025WO
[0386] In some embodiments, an instance of R41 is D. In some embodiments, an instance of Ru is halogen. In some embodiments, an instance of R41 is -OH. In some embodiments, an instance of R41 is (C3-C?)carbocyclyl. In some embodiments, an instance of R41 is phenyl optionally substituted with one or more R17. In some embodiments, an instance of R41 is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH. and S, wherein heteroaryl is optionally substituted with one or more R17.
[0387] In some embodiments, an instance of R42 is H. In some embodiments, an instance of R42 is (Ci-Ce)alkyl optionally substituted with one or more R17. In some embodiments, an instance of R42 is Si((Ci-C6)alkyl)3, wherein each alkyl is optionally substituted with one or more R17. In some embodiments, an instance of R42 is phenyl optionally substituted with one or more R17. In some embodiments, an instance of R42 is 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein heteroaryl is optionally substituted with one or more R17.
[0388] In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2.
[0389] In some embodiments, 0 is 0. In some embodiments, 0 is 1. In some embodiments, 0 is 2.
[0390] In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4.
[0391] In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3.
[0392] In some embodiments, r is 0. In some embodiments, r is 1.
[0393] Non-limiting illustrative compounds of the disclosure include the compounds in Table 1:
[0394] Table 1. Exemplary compounds of Formula (I)
[0395]
[0396] Attorney Docket No.: N2109-7025WO
[0397]
[0398] Attorney Docket No.: N2109-7025WO
[0399]
[0400] * Absolute and relative stereochemistry was not assigned.
[0401] In another embodiment of the disclosure, the compounds of the present disclosure are enantiomers. In some embodiments the compounds are the (S)-enantiomer. In other embodiments the compounds are the (R)-enantiomer. In yet other embodiments, the compounds of the present disclosure may be (+) or (-) enantiomers.
[0402] It should be understood that all isomeric forms are included within the present disclosure, including mixtures thereof. If the compound contains a double bond, the substituent may be in the E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.Attorney Docket No.: N2109-7025WO
[0403] Compounds of the disclosure, and pharmaceutically acceptable salts, hydrates, solvates, stereoisomers, and prodrugs thereof may exist in their tautomeric form (for example, as an amide or iminic acid). All such tautomeric forms are contemplated herein as part of the present disclosure.
[0404] Tire compounds of the disclosure may contain asymmetric or chiral centers and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric fonns of the compounds of the disclosure as well as mixtures thereof, including racemic mixtures, form part of the present disclosure. In addition, the present disclosure embraces all geometric and positional isomers. For example, if a compound of the disclosure incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the disclosure. Each compound herein disclosed includes all the enantiomers that conform to the general structure of the compound. The compounds may be in a racemic or enantiomerically pure fonn, or any other form in terms of stereochemistry. The assay results may reflect the data collected for the racemic form, the enantiomerically pure form, or any other form in terms of stereochemistry.
[0405] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Masher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers or via chiral chromatography. Also, some of the compounds of the disclosure may be atropisomers (e.g., substituted biaryls) and are considered as part of this disclosure. Enantiomers can also be separated by use of a chiral HPLC column.
[0406] It is also possible that the compounds of the disclosure may exist in different tautomeric forms, and all such forms are embraced within the scope of the disclosure and chemical structures and names. Also, for example, all keto-enol and imine-enamine forms of the compounds are included in the disclosure.
[0407] All stereoisomers (for example, geometric isomers, optical isomers, and the like) of the present compounds (including those of the salts, solvates, esters, and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this disclosure, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). (For example, if a Compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, arc embraced within the scope of the disclosure. Also, for example, all kcto-cnol and imine-enamine fonns of the compounds are included in the disclosure.) Individual stereoisomers of theAttorney Docket No.: N2109-7025WO
[0408] compounds of the disclosure may, for example, be substantially free of other isomers, or is admixed, for example, as racemates or with all other, or other selected, stereoisomers.
[0409] Tire chiral centers of the compounds of the disclosure can have the S or R configuration as defined by the IUPAC 1974 Recommendations. In certain embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)- configuration. Substituents at atoms with unsaturated double bonds may, if possible, be present in cis-(Z)- or trans-(E)- form.
[0410] Tire use of the terms "salt", "solvate", "ester," "prodrug", and the like, is intended to equally apply to the salt, solvate, ester, and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates, or prodrugs of tire inventive compounds.
[0411] The compounds of tire disclosure may form salts which are also within the scope of this disclosure. Reference to a compound of the Formula herein is generally understood to include reference to salts thereof, unless otherwise indicated.
[0412] Tire compounds and intermediates may be isolated and used as the compound per se. Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the fonnulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and, such as2H,3H,nC,13C,14C,15N,18F,31P,32P, respectively.
[0413] Tire disclosure includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as3H,13C, and14C, are present. Such isotopically labelled compounds are useful in metabolic studies (with14C), reaction kinetic studies (with, for example2H or3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an18F, lie or labeled compound may be particularly desirable for PET or SPECT studies.
[0414] Further, substitution with heavier isotopes, particularly deuterium (i.e.,2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life, reduced dosage requirements, reduced CYP450 inhibition (competitive or time dependent) or an improvement in therapeutic index. For example, substitution with deuterium may modulate undesirable side effects of the undeuterated compound, such as competitive CYP450 inhibition, time dependent CYP450 inactivation, etc. It is understood that deuterium in this context is regarded as a substituent in compounds of the present disclosure. The concentration of such a heavier isotope, specifically deuterium,Attorney Docket No.: N2109-7025WO
[0415] may be defined by the isotopic enrichment factor. The term "isotopic enrichment factor" as used herein means tire ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this disclosure is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation, at 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
[0416] Isotopically-labeled compounds of the present disclosure can generally be prepared by conventional techniques known to those skilled in the art or by carrying out the procedures disclosed in the schemes or in the examples and preparations described below using an appropriate isotopically-labeled reagent in place of the non-isotopically labeled reagent.
[0417] Pharmaceutically acceptable solvates in accordance with the disclosure include those wherein the solvent of crystallization may be isotopically substituted, e.g., D2O, d6-acetone, d6-DMSO.
[0418] The present disclosure relates to compounds which are modulators of HIF-lb protein levels. In one embodiment, the compounds of the present disclosure decrease HIF-lb protein levels. In yet one embodiment, the compounds of the present disclosure reduce HIF-lb protein levels. In another embodiment, the compounds of the present disclosure are degraders of HIF-lb.
[0419] As used herein, the term “IC50” refers to half maximal inhibitory concentration. As used herein, the term “DC50” refers to half maximal degradation concentration. As used herein, the term “EC50” refers to half maximal effective concentration. As used herein, the term “AC50” refers to half maximal activation. As used herein, Dmax is the maximum level of degradation achievable.
[0420] In some embodiments, the degradation of HIF-lb is measured by DC50.
[0421] Potency of a compound of the present disclosure towards degradation of HIF-lb can be measured by its DC 50 value. A compound with a lower DC50 value, as determined under substantially similar degradation conditions, is a more potent degrader relative to a compound with a higher DC50 value. In some embodiments, the substantially similar conditions comprise determining degradation of protein levels in cells expressing the specific protein, or a fragment of any thereof. As used herein, Dmax is the maximum level of degradation achievable.
[0422] In some embodiments, a compound of the present disclosure exhibits selectivity for HIF-lb over another target, such as IKZF1, IKZF2, IKZF3, CKla. SALL4, or GSPT1. Selectivity for modulating the degradation of one target protein (e.g., HIF-lb) over another protein may be measured using any number of methods known in the art. In some embodiments, a compound of Formula (I) or a pharmaceuticallyAttorney Docket No.: N2109-7025WO
[0423] acceptable salt thereof exhibits selectivity for degradation of HIF-lb over another protein (e.g., IKZF1, IKZF2, IKZF3, CKla. SALL4, or GSPT1) at a ratio of greater than 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, or 100.
[0424] In some embodiments, a compound of the present disclosure exhibits improved cell membrane permeability upon administration to a cell or subject compared to another compound, e.g., in a standard assay for measuring cell permeability. In some embodiments, a compound of the present disclosure exhibits improved cell viability upon administration to a cell or subject compared with another compound, e.g., in a standard assay for measuring cell viability. In some embodiments, a compound of the present disclosure exhibits improved metabolic stability upon administration to a cell or subject compared with another compound, e.g., in a standard assay for measuring metabolic stability. In some embodiments, a compound of the present disclosure exhibits reduced hERG inhibition upon administration to a cell or subject compared with another compound, e.g., in a standard assay for measuring hERG inhibition.
[0425] The disclosure is directed to compounds as described herein and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof, and pharmaceutical compositions comprising one or more compounds as described herein, or pharmaceutically acceptable salts, hydrates, solvates, prodrugs, stereoisomers, or tautomers thereof.
[0426] F. Methods of Synthesizing Compounds of Formula (I)
[0427] The compounds of the present disclosure may be made by a variety of methods, including standard chemistry. Suitable synthetic routes are depicted in the Schemes given below.
[0428] The compounds of the present disclosure may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthetic schemes. In the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles or chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Greene and P. G. M. Writs, " Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection processes, as well as tire reaction conditions and order of their execution, shall be consistent with the preparation of Compounds of Formula (I).
[0429] Those skilled in the art will recognize if a stcrcoccntcr exists in the compounds of the present disclosure. Accordingly, the present disclosure includes all possible stereoisomers (unless specified in the synthesis) and includes not only racemic compounds but the individual enantiomers and / or diastereomers as well. When a compound is desired as a single enantiomer or diastereomer, it may be obtained by stereo specific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be affected by any suitable method known in theAttorney Docket No.: N2109-7025WO
[0430] art. See, for example, " Stereochemistry of Organic Compounds" by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).
[0431] Tire compounds described herein may be made from commercially available starting materials or synthesized using known organic, inorganic, and / or enzymatic processes.
[0432] A mixture of enantiomers, diastereomers, and cis / trans isomers resulting from the synthetic process described above can be separated into their single components by chiral salt technique, chromatography using normal phase, reverse phase or chiral column, depending on the nature of the separation.
[0433] Any resulting racemates of compounds of the present disclosure or of intennediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound. In particular, a basic moiety may thus be employed to resolve the compounds of the present disclosure into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O, O’-p-toluoyl tartaric acid, mandelic acid, malic acid, or camphor- 10-sulfonic acid. Racemic compounds of the present disclosure or racemic intermediates can also be resolved by chiral chromatography, e.g.. high pressure liquid chromatography (HPLC) using a chiral adsorbent.
[0434] Any resulting mixtures of stereoisomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and / or fractional cry stallization.
[0435] G. Methods of Using Compounds of Formula (I)
[0436] In one aspect of the disclosure relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder in a patient associated with or affected by modulation of HIF-lb protein levels. Hie method comprises administering to a patient in need of a treatment for diseases or disorders associated with modulation of HIF-lb protein levels an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. Examples of diseases or conditions associated with or affected by modulation of HIF-lb protein levels include, but not limited to, cell proliferative diseases and disorders (e.g., cancer or benign neoplasms), von Hippel-Lindau (VHL) disease, iron overload disorders, immune-related disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), inflammatory diseases and conditions, autoimmune diseases, neurodegenerative diseases, viral diseases, bacterial infections, fungal infections, parasitic infections, chronic and acute kidney diseases or injuries, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected fromAttorney Docket No.: N2109-7025WO
[0437] renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or nonHodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple-negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0438] In another aspect, the disclosure relates to a method of treating, preventing, inhibiting, or eliminating a disease or disorder that is affected by the reduction of or decrease in HIF-lb protein levels. The method comprises administering to a patient in need of a treatment for diseases or disorders affected by the reduction of HIF-lb protein levels an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, tire disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary' arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatcllitc stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloidAttorney Docket No.: N2109-7025WO
[0439] leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple -negative breast cancer (TNBC). In another embodiment, tire disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary? heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0440] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for the treatment, prevention, inhibition or elimination of a disease or disorder that is associated with or affected by the modulation of HIF-lb protein levels. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple-negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary¬ heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment,Attorney Docket No.: N2109-7025WO
[0441] the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple -negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is and coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0442] In another aspect, the disclosure relates to the use of a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for the treatment, prevention, inhibition or elimination of a disease or disorder that is affected by the reduction of or a decrease in HIF-lb protein levels. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple-negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasophary ngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatcllitc stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, theAttorney Docket No.: N2109-7025WO
[0443] disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0444] Another aspect of the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder that is associated with or affected by the modulation of HIF-lb protein levels. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple-negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasophary ngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0445] Another aspect of the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hy drate, solvate, prodrug, stereoisomer,Attorney Docket No.: N2109-7025WO
[0446] or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating a disease or disorder that is associated with or affected by the reduction of, or a decrease in HIF-lb protein levels. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple-negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0447] In another aspect, the present disclosure is directed to a method of modulating, reducing, or decreasing HIF-lb protein levels. Tire method involves administering to a patient in need thereof an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In some embodiments, HIF-lb protein levels are modulated, reduced, or decreased through degradation of the HIF-lb protein. In other embodiments, HIF-lb protein levels are modulated, reduced, or decreased through degradation of the HIF-lb protein mediated by an E3 ligase.Attorney Docket No.: N2109-7025WO
[0448] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, in the manufacture of a medicament for the treatment, prevention, inhibition or elimination of a disease or disorder that is associated with or affected by the modulation, reduction, decrease of HIF-lb protein levels. In some embodiments, HIF-lb protein levels are modulated, reduced, or decreased through degradation of the HIF-lb protein. In other embodiments, HIF-lb protein levels are modulated, reduced, or decreased through degradation of the HIF-lb protein mediated by an E3 ligase.
[0449] In another aspect, the present disclosure relates to a method of treating, preventing, inhibiting, or eliminating an HIF-lb-dependent disease or disorder in a patient in need thereof by modulating HIF-lb protein levels through the degradation of HIF-lb. In some embodiments, HIF-lb protein degradation is mediated by an E3 ligase.
[0450] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, for treating, preventing, inhibiting, or eliminating an HIF-lb-dependent disease or disorder in a patient in need thereof by modulating HIF-lb protein levels through the degradation of HIF-lb. In some embodiments, I HIF-lb protein degradation is mediated by an E3 ligase.
[0451] In another aspect, the present disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, for use in the treatment, prevention, inhibition or elimination of an HIF-lb-dependent disease or disorder in a patient in need thereof by modulating HIF-lb protein levels through the degradation of HIF-lb. In some embodiments, I HIF-lb protein degradation is mediated by an E3 ligase.
[0452] Another aspect of the disclosure relates to a method of reducing the proliferation of a cell, the method comprising contacting the cell with a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, that reduces HIF-lb protein levels. In some embodiments, HIF-lb protein levels are reduced through degradation of the HIF-lb protein. In some embodiments, HIF-lb protein levels arc reduced through degradation of the HIF-lb protein is mediated by an E3 ligase.Attorney Docket No.: N2109-7025WO
[0453] Another aspect of the disclosure relates to a method of degrading HIF-lb. The method comprises administering to a patient in need thereof an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In some embodiments, HIF-lb protein degradation is mediated by an E3 ligase.
[0454] In another aspect, the present disclosure relates to amethod fortreating a HIF-lb-dependent disease or disorder. Tire method comprises the step of administering to a subject in need thereof a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or nonHodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasophary ngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple -negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). hr another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).Attorney Docket No.: N2109-7025WO
[0455] Another aspect of the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a HIF- Ib-dependent disease or disorder. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment, the disease or disorder is triple-negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, the disease or disorder is coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0456] In another aspect, the present disclosure relates to the use of a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a HIF-lb-dependent disease or disorder. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, vonAttorney Docket No.: N2109-7025WO
[0457] Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, the disease or disorder is melanoma. In yet another embodiment the disease or disorder is triple -negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, compounds of the present invention may be used to treat coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0458] Another aspect of the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating a HIF- Ib-dependent disease or disorder. In one embodiment, the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases. In another embodiment, the disease or disorder is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, colitis, Crohn's disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease. In one embodiment, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis. In another embodiment, compounds ofAttorney Docket No.: N2109-7025WO
[0459] the present invention may be used to treat T cell leukemia or T cell lymphoma. In yet another embodiment, the disease or disorder is Hodgkin’s lymphoma or non-Hodgkin’s lymphoma. In another embodiment, the disease or disorder is non-small cell lung cancer (NSCLC). In yet another embodiment, the disease or disorder is renal cell carcinoma (RCC). In one embodiment, renal cell carcinoma is clear cell renal cell carcinoma (ccRCC). In another embodiment, tire disease or disorder is melanoma. In yet another embodiment the disease or disorder is triple -negative breast cancer (TNBC). In another embodiment, the disease or disorder is nasopharyngeal cancer (NPC). In yet another embodiment, the disease or disorder is microsatellite stable colorectal cancer (mssCRC). In another embodiment, the disease or disorder is thymoma. In yet another embodiment, the disease or disorder is carcinoid. In another embodiment, the disease or disorder is gastrointestinal stromal tumor (GIST). In yet another embodiment, the disease or disorder is myeloid leukemia. In another embodiment, compounds of the present invention may be used to treat coronary heart disease. In yet another embodiment, the disease or disorder is pulmonary arterial hypertension (PAH).
[0460] In another aspect, the present disclosure relates to a method of reducing HIF-lb protein levels. The method comprises administering to the patient in need thereof a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0461] In another aspect, the present disclosure relates to a method of reducing HIF-lb protein levels, wherein reduction of HIF-lb protein levels treats or ameliorates the disease or disorder. Tire method comprises administering to the patient in need thereof a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0462] In another aspect, the disclosure relates to a method of treating, preventing, inhibiting, or eliminating von Hippel-Lindau (VHL) disease. The method comprises administering to a patient in need of a treatment for VHL disease an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0463] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmacally acceptable salt, hydrate,Attorney Docket No.: N2109-7025WO
[0464] solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for the treatment, prevention, inhibition or elimination of von Hippel-Lindau (VHL) disease.
[0465] In another aspect, the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating von Hippel-Lindau (VHL) disease.
[0466] In one embodiment, the patient suffering from VHL disease also suffers from hemangioblastoma, a pheochromocytoma, a pancreatic neuroendocrine tumor or renal cell carcinoma.
[0467] In another embodiment, the patient suffering from VHL disease also suffers from renal cell carcinoma.
[0468] In another aspect, the disclosure relates to a method of treating, preventing, inhibiting, or eliminating renal cell carcinoma (RCC). The method comprises administering to a patient in need of a treatment for renal cell carcinoma an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0469] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodmg, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for the treatment, prevention, inhibition or elimination of renal cell carcinoma.
[0470] In another aspect, the disclosure relates to a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodmg, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodmg, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for treating, preventing, inhibiting, or eliminating renal cell carcinoma. In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
[0471] In another aspect, the disclosure relates to a method of reducing inflammation of the digestive system in a patient in need thereof. The method comprises administering to a patient in need of reduction in inflammation an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodmg, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodmg, stereoisomer, or tautomer thereof. In one embodiment, the patient suffers from inflammatory bowel disease. In another embodiment,Attorney Docket No.: N2109-7025WO
[0472] the patient suffers from Crohn’s disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration of a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0473] Another aspect of the disclosure relates to the use of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for reducing inflammation of the digestive system in a patient in need thereof. In one embodiment, the patient suffers from inflammatory bowel disease. In another embodiment, the patient suffers from Crohn's disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration of a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0474] In another aspect, the disclosure relates to a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for reducing inflammation of the digestive system in a patient in need thereof. In one embodiment, the patient suffers from inflammatory bowel disease. In another embodiment, the patient suffers from Crohn’s disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration of a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0475] Another aspect of the disclosure relates to a method of reducing inflammation of the digestive system. The method comprises administering to a patient in need of a treatment in need of reduction in inflammation of the digestive system an effective amount of a HIF-lb modulator Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In one embodiment, the patient suffers from inflammatory’ bowel disease. In another embodiment, the patient suffers from Crohn’s disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration ofAttorney Docket No.: N2109-7025WO
[0476] a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0477] Another aspect of the disclosure relates to the use of a HIF-lb modulator Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for reducing inflammation of the digestive system in a patient in need thereof. In one embodiment, the patient suffers from inflammatory bowel disease. In another embodiment, the patient suffers from Crohn's disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration of a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0478] In another aspect, the disclosure relates to a HIF-lb modulator Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the manufacture of a medicament for reducing inflammation of the digestive system in a patient in need thereof. In one embodiment, the patient suffers from inflammatory' bowel disease. In another embodiment, the patient suffers from Crohn’s disease or colitis. In another embodiment, the patient suffers from ulcerative colitis. In one embodiment, the administration of a compound of the present disclosure induces remission of the inflammation. In another embodiment, the administration of a compound of the present disclosure reduces intestinal inflammation. In yet another embodiment, the administration of a compound of the present disclosure inhibits recruitment of inflammatory cells.
[0479] Examples of cell proliferative diseases and disorders (e.g., cancers) that can be treated with compounds of the present disclosure include, but are not limited to, acanthoma, acinic cell carcinoma, acoustic neuroma, acral lentiginous melanoma, acrospiroma, acute eosinophilic leukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloid dendritic cell leukemia, acute myeloid leukemia, acute promyelocytic leukemia, adamantinoma, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor, adrenocortical carcinoma, adult T-ccll leukemia, aggressive NK-ccll leukemia, agnogenic myeloid metaplasia, AIDS-related cancers, AIDS-related lymphoma. ALK+Attorney Docket No.: N2109-7025WO
[0480] anaplastic large cell lymphoma, alveolar soft part sarcoma, ameloblastic fibroma, anal cancer, anaplastic large cell lymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma, angiomyolipoma, angiosarcoma, appendix cancer, astrocytoma, atypical teratoid rhabdoid tumor, basal cell carcinoma, basal-like carcinoma, B-cell leukemia, B-cell lymphoma, B-cell non-Hodgkin’s lymphoma, bellini duct carcinoma, benign monoclonal gammopathy, biliary cancer, biliary tract cancer, bladder cancer, blastoma, bone cancer, bone tumor, brain stem glioma, brain cancer, brain tumor, breast cancer, brenner tumor, bronchial tumor, bronchial adenomas / carcinoids, bronchioloalveolar carcinoma, brown tumor, Burkitt’s lymphoma / leukemia, carcinoid tumor, carcinoma, carcinosarcoma, Castleman’s disease, central nervous system embryonal tumor, cerebellar astrocytoma, cerebral astrocytoma, cervical cancer, cholangiocarcinoma, chondroma, chondrosarcoma, chordoma, choriocarcinoma, choroid plexus papilloma, chronic lymphocytic leukemia, chronic monocytic leukemia, chronic myelocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorder, chronic neutrophilic leukemia, clear cell renal cell carcinoma, clear-cell tumor, colon cancer, colorectal cancer, craniophary ngioma, cutaneous T-cell lymphoma, dermatofibrosarcoma protuberans, dermoid cyst, desmoplastic small round cell tumor, diffuse large B cell lymphoma (DLBCL) (e.g., germinal center B-cell-like diffuse large B-cell lymphoma or activated B-cell-like diffuse large B-cell lymphoma), dysembryoplastic neuroepithelial tumor, embryonal carcinoma, endodermal sinus tumor, endometrial cancer, endometrial uterine cancer, endometrioid tumor, enteropathy-associated T-cell lymphoma, ependymoblastoma, ependymoma, epithelioid sarcoma, erythroleukemia, esophageal cancer, essential thrombocythemia, esthesioneuroblastoma, Ewing’s sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, extrahepatic cholangiocarcinoma extramammary' Paget’s disease, fallopian tube cancer, fibroma, fibrosarcoma, follicular lymphoma (FL), follicular thyroid cancer, gallbladder cancer, ganglioglioma, ganglioneuroma, gastric cancer, gastric lymphoma, gastrointestinal cancer, gastrointestinal / stomach (GIST) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, germinoma, gestational choriocarcinoma, gestational trophoblastic tumor, gestational trophoblastic tumor glioma, giant cell tumor of bone, glioblastoma, glioblastoma multiforme (GBM), glioma, gliomatosis cerebri, glomus tumor, glucagonoma, gonadoblastoma, granulosa cell tumor, hairy cell leukemia, head and neck cancer, heart cancer, hemangioblastoma, hemangioendothelioma, hemangiopericytoma, hemangiosarcoma, hematological malignancy, hepatocellular carcinoma, hepatosplenic T-cell lymphoma. Hodgkin’s lymphoma, hypopharyngeal cancer, hypothalamic glioma, inflammatory breast cancer, intrahepatic bile duct cancer, intraocular (eye) melanoma, intrahepatic cholangiocarcinoma, islet cell tumors (endocrine, pancreas), islet cell carcinoma, islet cell pancreatic cancer, myxosarcoma, myxosarcoma enile, myclomonocytic leukemia, Kaposi’s sarcoma, kidney cancer, klatskin tumor, krukenberg tumor, laryngeal cancer, leiomyosarcoma, lentigo maligna melanoma, leukemia, lip and oral cavity cancer, liposarcoma,Attorney Docket No.: N2109-7025WO
[0481] liver cancer, lung cancer, luteoma, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoid leukemia, lymphoid neoplasm, lymphoma, lymphomatoid papulosis, lymphoplasmacytic lymphoma, macroglobulinemia, malignant fibrous histiocytoma, malignant glioma, malignant mesothelioma, malignant peripheral nerve sheath tumor, malignant rhabdoid tumor, malignant triton tumor, malt lymphoma, mantle cell lymphoma (MCL), mast cell leukemia, mast cell neoplasms, mediastinal germ cell tumor, mediastinal tumor, mediastinal (thymic) large B-cell lymphoma, medullary thyroid cancer, medulloblastoma, medulloepithelioma, melanoma, meningioma, merkel cell carcinoma, mcscnchymous or mixed mesodermal tumor, mesothelioma, mesothelial sarcoma, metastatic pancreatic adenocarcinoma, metastatic squamous neck cancer with occult primary', metastatic urothelial carcinoma, mixed mullerian tumor, monocytic leukemia, mouth cancer, mucinous tumor, multiple endocrine neoplasia (MEN), multiple endocrine neoplasia syndrome, multiple myeloma, mycosis fungoides. myelodysplasia, myelodysplastic disease / syndromes, myeloid leukemia, myeloid neoplasms, myeloid sarcoma, myeloproliferative disease, myxoma, nasal cavity cancer, nasopharyngeal cancer, neoplasm, nervous system cancer (e.g., central nervous system cancer, central nervous system lymphoma), neurinoma, neuroblastoma, neurofibroma, neuroma, nodular melanoma, non-Hodgkin’s lymphoma, nonmelanoma skin cancer, non-small cell lung cancer, ocular cancer, oligoastrocytoma, oligodendroglioma, oncocytoma, optic nerve sheath meningioma, oral cancer, oropharyngeal cancer, osteogenic sarcoma, osteosarcoma, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, pancoast tumor, pancreatic cancer, pancreatic neuroendocrine tumor, papillary thyroid cancer, papillomatosis, paraganglioma, paranasal sinus cancer, parathyroid cancer, penile cancer, perivascular epithelioid cell tumor, pharyngeal cancer, pheochromocytoma, pineal parenchymal tumor of intermediate differentiation, pineoblastoma, pituicytoma, pituitary adenoma, pituitary tumor, plasma cell neoplasm, pleuropulmonary blastoma, polycythemia vera, polyembryoma, precursor T-lymphoblastic lymphoma, primitive neuroectodermal tumor, prostate cancer (e.g., metastatic castration resistant prostate cancer), pseudomyxoma peritonei, rectal cancer, refractory B-cell non-Hodgkin’s lymphoma, relapsed B-cell non-Hodgkin’s lymphoma, renal cancer, renal cell carcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter’s transformation, sacrococcygeal teratoma, salivary gland cancer, sarcoma, schwannomatosis, sebaceous gland carcinoma, secondary neoplasm, seminoma, serous tumor, Sertoli-Leydig cell tumor, sex cord-stromal tumor, sezary syndrome, signet ring cell carcinoma, skin cancer (non-melanoma), small blue round cell tumor, small cell carcinoma, small cell lung cancer, small cell lymphoma, small intestine cancer, small lymphocytic leukemia, small lymphocytic ly mphoma, soft tissue sarcoma, somatostatinoma, soot wart, spinal tumor, splenic marginal zone lymphoma, squamous cell carcinoma, stomach cancer, superficial spreading melanoma, supratentorial primitive neuroectodermal tumor, surface epithelial-stromal tumor, synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia,Attorney Docket No.: N2109-7025WO
[0482] T-cell lymphoma, T-cell prolymphocytic leukemia, teratoma, terminal lymphatic cancer, testicular cancer, thecoma, throat cancer, thymic carcinoma, thymoma, thyroid cancer (medullary and papillary7thyroid carcinoma), tongue cancer, transitional cell cancer of renal pelvis and ureter, transitional cell carcinoma, transitional cell cancer of the renal pelvis and ureter and other urinary organs, urachal cancer, urethral cancer, urinary bladder cancer, urogenital neoplasm, uterine cancer, uterine sarcoma, uveal melanoma, vaginal cancer, vemer morrison syndrome, verrucous carcinoma, visual pathway glioma, vulvar cancer, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, renal carcinoma, kidney parenchyma carcinoma, cervix carcinoma, cervix cancer, uterine corpus carcinoma, uterine corpus cancer, endometrium carcinoma, chorion carcinoma, testis carcinoma, urinary carcinoma, brain tumors such as glioblastoma, medulloblastoma and peripheral neuroectodermal tumors, gall bladder carcinoma, bronchial carcinoma, basalioma, choroidea melanoma, craniopharyngeoma. myosarcoma, fibrosarcoma, colon carcinoma, familiary adenomatous polyposis carcinoma, and hereditary non -polyposis colorectal cancer, melanoma, plasmocytoma. Waldenstrom’s macroglobulinemia, Warthin’s tumor, visual pathway and hypothalamic glioma, and Wilms’ tumor, or any combination thereof.
[0483] Examples of other diseases or disorders that can be treated with compounds of the present disclosure include, but are not limited to, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, autoimmune and inflammatory-related diseases and conditions, pulmonary arterial hypertension (PAH), neurodegenerative diseases, viral diseases, chronic and acute kidney diseases or injuries, metabolic diseases, allergic and genetic diseases, etc.) that can be treated with compounds of the present disclosure include, but are not limited to, pulmonary arterial hypertension (e.g., primary or secondary iron overload disorders including, but not limited to, hemochromatosis (e.g., iron hemochromatosis. HFE mutation hemochromatosis, ferroportin mutation hemochromatosis, transferrin receptor 2 mutation hemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutation hemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis), polycythemia (e.g., polycythemia vera), Pacak-Zhuang Syndrome, erythrocytosis, porphyria cutanea tarda, hereditary spherocytosis, hy prochromic anemia, hysererythropoietic anemia (CDAI), faciogenital dysplasia (FGDY), Aarskog syndrome, atransferrinemia, sideroblastic anemia (SA), aplastic anemia, pure red cell anemia, pyridoxine-responsive sidero-blastic anemia, and hemoglobinopathies such as thalassemia and sickle cell disease, cardiac ischemia, and pulmonary arterial hypertension; idiopathic PAH. heritable PAH (e.g., BMPR2, ALK 1, endoglin), drug -induced PAH, toxin-induced PAH, and PAH associated with another condition (e.g., connective tissue diseases, HIV infection, HIV-1, HIV-2, human T-cell leukemia virus-I (HTLV-I), HTLV-II, HTLV-III, simian immunodeficiency virus (SIV), lymphadenopathy associated virus (LAV-2), simian T-lymphotrophic virus-I (STLV-I), STLV-II, STLV-III, simian B-ly mphotrophic (SBL)Attorney Docket No.: N2109-7025WO
[0484] virus, Gibbon ape leukemia virus (GALV), bovine leukemia virus (BLV), equine infectious anemia virus (EIAV), feline leukemia virus (FELV), murine leukemia virus (MuLV), avian leukosis virus (ALV), other virus infections such as hepadnaviridae (Hepatitis B), herpesviridae (Herpes simplex I, Herpes simplex II, Varicella-Zoster, Herpes Zoster, Epstein-Barr virus and cytomegalovirus), parvoviridae (human parvovirus B-19), papovaviridae (human papilloma virus types I to 60, JC and BK viruses), pox viruses (variola major, variola minor, vaccinia, monkey pox, cowpox, paravaccinia or milker’s node virus, parapox or ORF virus, molluscum contagiosum, AIDS, influenza vims cytomegalovirus, portal hypertension, congenital heart diseases, schistosomiasis, or chronic hemolytic anemia), arthritis (e.g., rheumatoid arthritis), kidney failure, lupus, asthma, psoriasis, pancreatitis, hyaline membrane disease, allergies, fibrosis, surgical complications (e.g., where inflammatory cytokines prevent healing), anemia, fibromyalgia, Alzheimer’s disease, chronic heart failure, congestive heart failure, stroke, aortic valve stenosis, arteriosclerosis, acute coronary syndrome, osteoporosis. Parkinson’s disease, infections, inflammatory bowel disease (e.g.. Crohn’s disease and colitis such as ulcerative colitis), chronic obstructive pulmonary disease (COPD), atherosclerosis, glomerular disease, allergic contact dermatitis and other eczemas, atopic dermatitis, dermatitis herpetiformis, erythema multiforma, systemic sclerosis, transplantation multiple sclerosis, type II diabetes, multiple sclerosis, chronic gastritis, irritable bowel syndrome, cachexia, Graves’ disease, Bechteref s disease, myasthenia gravis, autoimmune hepatitis, autoimmune multiglandular endocrine insufficiency Disease (APECED), endocrine opthalmopathy. Churg-Strauss syndrome, glomerulonephritis (with and without nephrotic syndrome, e g. including idiopathic nephrotic syndrome or minal change nephropathy), nephritis, celiac disease, periodontitis, eosinophilic enteropathy, appendicitis, Guillain-Barre syndrome, Hashimoto’s disease, sclerosis of lichen, systemic lupus erythematosus, pediatric autoimmune streptococcal -related neuropsychiatric disorder (PANDAS), Rheumatic fever, sarcoidosis, Sjogren’s syndrome, systemic stiffness syndrome, scleroderma, Wegener’s granulomatosis, vitiligo, hypersensitivity angiitis, urticaria, bullous pemphigoid, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, epidermolysis bullosa acquisita, autoimmune enteropathy. Goodpasture syndrome, autoimmune allergic disease, allergic rhinitis, ocular allergy, allergic conjunctivitis, chronic granulomatous disease, asthma and organ transplantation, systemic lupus erythematosus, alopecia areata, anklosing spondylitis, antiphospholipid syndrome, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease, autoimmune lymphoproliferative syndrome (alps), autoimmune thrombocytopenic purpura (ATP), Behcet’s disease, vasculitis, diverticulitis, interstitial cystitis, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue syndrome immune deficiency, syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, cicatricial pemphigoid, cold agglutinin disease, Crest syndrome, Crohn's disease, Dcgo’s disease, dennatomyositis-juvenile, discoid lupus, essential mixed cr oglobulinemia, fibromyalgia-fibromyositis, guillain-barre, hashimoto’sAttorney Docket No.: N2109-7025WO
[0485] thyroiditis, idiopathic sprue, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA nephropathy, juvenile arthritis, systemic juvenile idiopathic arthritis, Meniere’s disease, mixed connective tissue disease, pernicious anemia, polyarteritis nodosa, polychondritis, polyglancular syndromes, acute lung injury, acute respiratory’ distress syndrome, polymyalgia rheumatica, cryopyrin-associated periodic syndrome, polymyositis and dennatomyositis. primary agammaglobulinemia, primary biliary cirrhosis, cirrhosis, Raynaud’s phenomenon. Reiter’s syndrome, rheumatic fever, sarcoidosis, alveolitis, stiff-man syndrome, Takayasu arteritis, temporal arteritis / giant cell arteritis, uveitis (anterior and posterior), vasculitis, Hashimoto’s thyroiditis, autoimmune hemolytic anemia, glaucoma, retinal disease, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, sepsis, septic shock, dacryoadenitis, cryopyrin associated periodic syndrome (CAPS), endotoxic shock, endometritis, gram-negative sepsis, CD 14 mediated sepsis, Steven-Johnson syndrome, non-CD14 mediated sepsis, keratoconjunctivitis sicca, vernal keratoconjunctivitis, vernal conjunctivitis, toxic shock syndrome, asthma, adult respiratory' distress syndrome, pulmonary disease, chronic pulmonary inflammation, chronic graft rejection, hidradenitis suppurativa, Goodpasture’s disease, autoimmune thrombocytopenia, sympathetic ophthalmia, juvenile -onset diabetes, Addison’s disease, lichen planus, bullous pemphigus, pemphigus vulgaris, pemphigus foliaceus, paraneoplastic pemphigus, immunoglobulin A nephropathy, Wegener granulomatosis, granulomatous orchitis, autoimmune oophoritis, psoriatic arthritis, acute and chronic renal disease, leptospiriosis renal disease, pancreatic fibrosis, hepatic fibrosis, sarcoidosis, rheumatic carditis, pyresis, restenosis, cervicitis, stroke and ischemic injury, neural trauma, acute and chronic pain, chronic aggressive and active hepatitis, membranous glomerulopathy, malaria, leprosy, leishmaniasis, Lyme disease, acute synovitis, muscle degeneration, bursitis, tendonitis, tenosynovitis, herniated, ruptured, or prolapsed intervertebral disk syndrome, osteopetrosis, rhinosinusitis, thrombosis, silicosis, pulmonary sarcosis, 22ql 1.2 deletion syndrome, Angelman syndrome, Canavan disease, Charcot-Marie-Tooth disease, color blindness, Cri du chat, Down syndrome, cystic fibrosis. Duchenne muscular dystrophy, haemophilia, Klinefleter’s symdrome, neurofibromatosis, phenylketonuria, Prader-Willi syndrome, Tay-Sachs disease, Turner syndrome, urea cycle disorders, otitis, parotitis, pericarditis, peritonitis, phary ngitis, pleuritis, phlebitis, pneumonitis, chronic hypersensitivity pneumonitis, interstitial lung fibrosis, amyotrophic lateral sclerosis, asociality, varicosis, vaginitis, depression, Sudden Infant Death Syndrome, gout, asbestosis, alcoholic liver disease, nonalcoholic steatohepatitis, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, macular degeneration, proliferative retinopathy, macular edema, retinopathy of prematurity, ascites, pleural effusion, cerebral oedema, pulmonary' oedema, ischemic heart disease, cerebrovascular disorders, endometriosis, insulin resistance, and obesity, or any combination thereof.Attorney Docket No.: N2109-7025WO
[0486] In one embodiment of the methods herein above, the disease or condition is selected from renal cell carcinoma, von Hippel-Lindau disease, pulmonary arterial hypertension, glioblastoma, and colitis.
[0487] In some embodiments, the compounds of the present invention may be used to treat T cell leukemia or T cell lymphoma.
[0488] In some embodiments, the compounds of the present invention may be used to treat Hodgkin’s lymphoma or non-Hodgkin’s lymphoma.
[0489] In some embodiments, the compounds of the present invention may be used to treat on-small cell lung cancer (NSCLC).
[0490] In some embodiments, the compounds of the present invention may be used to renal cell carcinoma (RCC). In one embodiment, the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
[0491] In some embodiments, the compounds of the present invention may be used to treat melanoma. In some embodiments, the compounds of the present invention may be used to treat triple -negative breast cancer (TNBC).
[0492] In some embodiments, the compounds of the present invention may be used to treat nasopharyngeal cancer (NPC).
[0493] In some embodiments, the compounds of the present invention may be used to treat microsatellite stable colorectal cancer (mssCRC).
[0494] In some embodiments, the compounds of the present invention may be used to treat thymoma. In some embodiments, the compounds of the present invention may be used to treat carcinoid. In some embodiments, the compounds of the present invention may be used to treat gastrointestinal stromal tumor (GIST).
[0495] In some embodiments, the compounds of the present invention may be used to treat myeloid leukemia.
[0496] In some embodiments, the compounds of the present invention may be used to treat coronary heart disease.
[0497] In some embodiments, the compounds of the present invention may be used to pulmonary arterial hypertension (PAH).
[0498] In one embodiment, the present disclosure provides a method of treating, preventing, inhibiting, or eliminating a proliferative disorder in a patient in need thereof. Tire method comprises administering to a patient in need of a treatment for said proliferative disorder an effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof or a composition comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof. In some embodiments, the proliferative disorder is a HIF-10-dependent or HIF-1 -associated proliferative disorder. In one embodiment, the proliferativeAttorney Docket No.: N2109-7025WO
[0499] disorder is a cancer. Representative cancers that compounds of Formula (I), are useful for treating, preventing, inhibiting, or eliminating include, but are not limited to, cancer of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.
[0500] In some embodiments, the cancer is a cancer selected from the group consisting of lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, breast cancer, ovarian cancer, renal cell carcinoma, prostate cancer, neuroendocrine cancer, gastric cancer, bladder cancer, uterus cancer, testes cancer, kidney cancer, skin cancer, gastrointestinal tract cancer (e.g, esophagus, oropharynx, stomach, small or large intestines, colon, or rectum), cervix cancer, and colon cancer. In some further embodiments, said cancer condition is a cancer selected from the group consisting of lung cancer, head and neck squamous cell carcinoma, pancreatic cancer, breast cancer, ovarian cancer, renal cell carcinoma, prostate cancer, neuroendocrine cancer, gastric cancer, bladder cancer and colon cancer. In some further embodiments, the cancer condition is selected from the group consisting of non-small-cell lung carcinoma, melanoma, renal cell carcinoma, colorectal cancer, castration-resistant prostate cancer, hepatocellular carcinoma, squamous cell carcinoma of the head and neck, carcinomas of the esophagus, ovary, gastrointestinal tract and breast, and a hematologic malignancy. In another embodiment, the cancer is selected from the group consisting of bladder cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and melanoma. In another embodiment, the cancer condition is renal cell carcinoma (RCC).
[0501] In a further embodiment, the present disclosure provides a method of treating a cancer condition, wherein the HIF-2a inhibitor is effective in one or more of inhibiting proliferation of cancer cells, inhibiting metastasis of cancer cells, killing cancer cells and reducing severity or incidence of symptoms associated with the presence of cancer cells. In some other embodiments, said method comprises administering to the cancer cells a therapeutically effective amount of a HIF-2a inhibitor. In some embodiments, the administration takes place in vitro. In other embodiments, the administration takes place in vivo.
[0502] In certain embodiments, the cancer is metastatic. In some embodiments, the cancer is relapsed. In other embodiments, the cancer is refractory. In yet other embodiments, the cancer is relapsed and refractory. In yet still another embodiment, the cancer is VHL-deficient RCC.
[0503] In another embodiment, the cancer is bladder cancer. In yet another embodiment, the cancer is breast cancer. In another embodiment, the cancer is NSCLC. In still another embodiment, the cancer is CRC. In another embodiment, the cancer is RCC. In yet another embodiment, the cancer is HCC. In another embodiment, the cancer is melanoma.Attorney Docket No.: N2109-7025WO
[0504] In one embodiment, the cancer is advanced RCC. In another embodiment, the RCC is advanced RCC with clear cell component (ccRCC). In yet another embodiment, the cancer is metastatic RCC. In yet another embodiment, the cancer is relapsed RCC. In another embodiment, the cancer is refractory RCC. In yet still another embodiment, the cancer is relapsed and refractory RCC. In another embodiment, the cancer is VHL-deficient RCC.
[0505] The disclosed compounds of the disclosure can be administered in effective amounts to treat or prevent a disorder and / or prevent the development thereof in subjects.
[0506] H. Administration, Pharmaceutical Compositions, and Dosing of Compounds of the Disclosure Administration of the disclosed compounds can be accomplished via any mode of administration for therapeutic agents. These modes include systemic or local administration such as oral, nasal, parenteral, transdermal, subcutaneous, vaginal, buccal, rectal or topical administration modes.
[0507] Depending on the intended mode of administration, the disclosed compositions can be in solid, semi-solid or liquid dosage form, such as, for example, injectables, tablets, suppositories, pills, time-release capsules, elixirs, tinctures, emulsions, syrups, powders, liquids, suspensions, or the like, sometimes in unit dosages and consistent with conventional pharmaceutical practices. Likewise, they can also be administered in intravenous (both bolus and infusion), intraperitoneal, subcutaneous, or intramuscular form, and all using forms well known to those skilled in the pharmaceutical arts.
[0508] Another aspect of the disclosure is directed to pharmaceutical compositions comprising a Compound of Formula (I), or a pharmacally acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, and a pharmacally acceptable carrier. The pharmaceutical acceptable carrier may further include an excipient, diluent, or surfactant. In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein. The pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g., by injection, infusion, transdermal or topical administration), and rectal administration. Topical administration may also pertain to inhalation or intranasal application. The pharmaceutical compositions of the present disclosure can be made up in a solid form (including, without limitation, capsules, tablets, pills, granules, powders or suppositories), or in a liquid fonn (including, without limitation, solutions, suspensions or emulsions). Tablets may be either film coated or enteric coated according to methods known in the art. Typically, the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with one or more of:
[0509] a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and / or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and / or polyethylene glycol; for tablets alsoAttorney Docket No.: N2109-7025WO
[0510] c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone; if desired
[0511] d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and e) absorbents, colorants, flavors and sweeteners.
[0512] Liquid, particularly injectable, compositions can, for example, be prepared by dissolution, dispersion, etc. For example, the disclosed compound is dissolved in or mixed with a pharmaceutically acceptable solvent such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form an injectable isotonic solution or suspension. Proteins such as albumin, chylomicron particles, or serum proteins can be used to solubilize the disclosed compounds.
[0513] Tire disclosed compounds can be also formulated as a suppository that can be prepared from fatty emulsions or suspensions; using polyalkylene glycols such as propylene glycol, as the carrier.
[0514] Parental injectable administration is generally used for subcutaneous, intramuscular or intravenous injections and infusions. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions or solid forms suitable for dissolving in liquid prior to injection.
[0515] Compositions can be prepared according to conventional mixing, granulating or coating methods, respectively, and the present pharmaceutical compositions can contain from about 0.1 % to about 99%, from about 5% to about 90%, or from about 1% to about 20% of the disclosed compound by weight or volume.
[0516] The dosage regimen utilizing the disclosed compound is selected in accordance with a variety of factors including type, species, age, weight, sex, and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal or hepatic function of the patient; and the particular disclosed compound employed. A physician or veterinarian of ordinary' skill in the art can readily detennine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[0517] Effective dosage amounts of the disclosed compounds, when used for the indicated effects, range from about 0.5 mg to about 5000 mg of the disclosed compound as needed to treat the condition. Compositions for in vivo or in vitro use can contain about 0.5, 5, 20, 50, 75, 100, 150, 250, 500, 750, 1000, 1250, 2500, 3500, or 5000 mg of the disclosed compound, or, in a range of from one amount to another amount in the list of doses. In one embodiment, the compositions are in the form of a tablet that can be scored. The therapeutically effective dosage of a compound, the pharmacal composition, or the combinations thereof, is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily detennine the effective amount of each of the active ingredients necessary' to prevent, treat or inhibit the progress of the disorder or disease.Attorney Docket No.: N2109-7025WO
[0518] The above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof. The compounds of the present disclosure can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution. The dosage in vitro may range between about 10-30 molar and 10-90 molar concentrations. A therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg / kg, or between about 1-100 mg / kg.
[0519] I. Combination Therapy
[0520] The compounds of the disclosure can be administered in therapeutically effective amounts in a combinational therapy with one or more therapeutic agents (pharmacal combinations) or modalities, e.g., non-drug therapies. For example, synergistic effects can occur with other cancer agents. Where the compounds of the application are administered in conjunction with other therapies, dosages of the coadministered compounds will of course vary' depending on the type of co-drug employed, on the specific drug employed, on the condition being treated and so forth.
[0521] The compounds can be administered simultaneously (as a single preparation or separate preparation), sequentially, separately, or over a period of time to the other drug therapy or treatment modality. In general, a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy. A therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the present disclosure.
[0522] In another aspect, the disclosure includes a Compound of Formula (I), Formula (F), Formula (la), Formula (laa), Formula (lb). Formula (Ibb), Formula (Ic), Formula (le), Formula (If), Formula (Ih), Formula (li). Formula (Ij), Formula (Ik), Formula (Im), Formula (Io), Formula (Ip), Formula (Iq), Formula (Is), Formula (lu), Formula (Iw), and / or Formula (ly), a compound according to any one of embodiment No. 1 to No. 70, or any embodiment of Formula (I), Fonnula (T), Formula (la), Formula (laa), Fonnula (lb), Fonnula (Ibb), Fonnula (Ic), Formula (le), Formula (If), Fonnula (Ih). Formula (li), Formula (Ij), Formula (Ik), Formula (Im), Fonnula (Io), Fonnula (Ip), Fonnula (Iq), Fonnula (Is), Formula (lu), Formula (Iw), and / or Formula (ly), described herein, or a pharmaceutically acceptable salt thereof, for use in a combination therapy. A compound, composition, medicament and compounds for use of Formula (I), Formula (T), Formula (la), Formula (laa), Formula (lb), Formula (Ibb), Formula (Ic), Formula (le), Fonnula (If), Formula (Ih), Formula (li), Fonnula (Ij), Fonnula (Ik), Formula (Im), Fonnula (Io), Formula (Ip), Formula (Iq), Formula (Is), Formula (lu), Formula (Iw), and / or Formula (ly), a compound according to any¬ one of embodiment No. 1 to No. 70, or any embodiment of Formula (I). Formula (F), Fonnula (la), FormulaAttorney Docket No.: N2109-7025WO
[0523] (laa), Formula (lb). Formula (Ibb), Formula (Ic), Formula (le). Formula (If), Formula (Ih), Formula (li), Formula (Ij), Formula (Ik), Formula (Im), Formula (Io), Formula (Ip), Formula (Iq), Formula (Is), Formula (lu), Formula (Iw), and / or Formula (ly), described herein, or a pharmaceutically acceptable salt thereof, may also be used to advantage in combination with one or more other therapeutic agents.
[0524] Another aspect of the disclosure is directed to pharmaceutical compositions comprising a Compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, a pharmaceutically acceptable carrier, and one or more therapeutic agents. The pharmaceutically acceptable carrier may further include an excipient, diluent, or surfactant.
[0525] Combination therapy includes the administration of the subject compounds in further combination with other biologically active ingredients (such as, but not limited to, a second agent such as, but not limited to. a second agent that targets HIF-lb (e.g., a second HIF-lb inhibitor or degrader), a second agent that targets one or more of the HIF transcription factors, non-drug therapies (such as. but not limited to, surgery or radiation treatment), anti-cancer agents, immune -modulators, therapeutic antibodies, anti-Von Hippel-Lindau disease agents, antibiotics, anti-inflammatory, immunosuppressive, vasoactive antiseptic agents (e.g., anti-bacterial agents, anti-fungicides, anti-viral agents, anti-parasitic agents, etc.), immunomodulatory agents, immuno -oncology agents, RNA interference-based therapies to silence gene expression, anti-nausea agents (or anti-emetics), pain relievers, cytoprotective agents, cardiovascular agents, hypertension agents, and combinations thereof.
[0526] “Combination therapy” is intended to embrace administration of these therapeutic agents in a sequential manner, wherein each therapeutic agent is administered at a different time and in any order, or in alternation and in any order, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
[0527] Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be affected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. Tire therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally, or all therapeutic agents may be administered by intravenous injection. The sequence in which the therapeutic agents are administered is not narrowly critical.
[0528] In accordance with the foregoing, tire present disclosure also provides a therapeutic combination, e.g., a kit, kit of parts, e.g., for use in any method as defined herein, comprising a Compound of FormulaAttorney Docket No.: N2109-7025WO
[0529] (I), or a pharmaceutically acceptable salt thereof, to be used concomitantly or in sequence with at least one pharmaceutical composition comprising at least one or more other therapeutic agents, or a pharmaceutically acceptable salt thereof. The kit may comprise instructions for its administration. The combination can be a fixed combination (e.g., in the same pharmaceutical composition) or a free combination (e.g., in separate pharmacal compositions).
[0530] Similarly, the present disclosure provides a kit of parts comprising: (i) a pharmaceutical composition of the disclosure; and (ii) a pharmaceutical composition comprising one or more other therapeutic agents, or a pharmaceutically acceptable salt thereof, in the form of two separate units of the components (i) to (ii).
[0531] Likewise, the present disclosure provides a method as defined above comprising co- administration, e.g., concomitantly or in sequence, of a therapeutically effective amount of a Compound of Formula (I), or a pharmaceutically acceptable salt thereof, and one or more other therapeutic agents.
[0532] ENUMERATED EMBODIMENTS
[0533] 1. A compound of F onnula (T ):
[0534]
[0535] pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:
[0536] Xi is N or CRy
[0537] X2is N, N(O), or CR5;
[0538] Ri is H, D, -C(O)Rn, -CH2OC(O)Rn, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(OR]2)2, -CH2OP(O)(ORi2)2, -CH2OP(O)(OH)ORi2. -CH2OP(O)(RI2)2, -CH2OC(O)CH2NHC(O)CH2NH2. -CH2OC(O)CH(R12)NHRI2, -CH2OC(O)(CH2)q-C(O)OR12, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);
[0539] R2a, Ra, R2C, and R2d are each independently H, D, (Ci-C,)alkyl. (Ci-Ce)deuteroalkyl, halogen, or -OH, wherein two of R2a, R2b, R2c, and RM may be taken together with the carbon atom to which they are attached form a (C3-C?)carbocyclyl or (C3-C7)spirocarbocyclyl optionally substituted with one or more Rw;
[0540] R3 is H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, or halogen, wherein Rsmay be taken together with one of R2a, Ra>, R2c, and RM with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl optionally substituted with one or more R40;Attorney Docket No.: N2109-7025WO
[0541] R4aand Rib are each independently H, D, (Ci-Cfi)alkyl, (Ci-CsJdeuteroalkyL (Ci -Cjhaloalkyl. (Ci-Ce)alkoxy, (Ci-Cejdeuteroalkoxy, (Ci-C6)haloalkoxy, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4-to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or -NR9R10; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40;
[0542] each R5 is independently H. D, (Ci-Ce)alkyl, (C -C,.)dcutcroalkyl. (Ci-C6)haloalkyl. (Ci-Ce)alkoxy, (Ci-C6)deuteroalkoxy, (Ci-Cs)haloalkoxy, (C3-C7)carbocyclyl, O(C3-C7)carbocyclyl, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; halogen, -OH, or -NR9R10, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40;
[0543] . is H, D, (Ci-Ce)hydroxyalkyl, (Ci-Ce)halohydroxyalkyl, (Ci-C6)aminoalkyl, (Ci-C6)alkyl-0-(Ci-C6)hydroxyalkyl, -C(0)Rn, -CH20C(0)Rn. -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(OH)ORI2, or -CH2OP(O)(RI2)2;
[0544] R?a, R7b, R?c, and
[0545]
[0546] are each independently H, D, (Ci-C)alkyl. (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, halogen, (Ci-C6)hydroxyalkyl, -CN, -OH, -O-(Ci-C. Jhydroxyalkyl. (Ce-Cio) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; or
[0547] two of R?a, R2b, R?c, and R?d are taken together with the carbon atoms to which they are attached form (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cs)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(O)ORis, -C(0)RB, and -C(O)NRis R13;
[0548] each R7eis independently at each occurrence D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, halogen, (Ci-C6)hydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, (Ce-Cio) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; orAttorney Docket No.: N2109-7025WO
[0549] two R?e together with the carbon atom to which they are attached form a (C3-C7)carbocyclyl, (C -C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-C6)alkyl, (Ci-C6)deuteroalkyl, (Ci-Ce)haloalkyl, (C’i-C„)alkoxy. (Ci-Ce)haloalkoxy. (Ci-C6)hydroxyalkyl. halogen, -C(0)0RB, -C(0)Ri3, and -C(O)NR13 R13 ■:
[0550] one R7e is taken together with any one of R?;. R?b, R?c. and R? J and the atoms to which they are attached form a (Cj-CvJcarbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22:
[0551] Rs is (Ci-C6)alkyl, (Ci-Ce)haloalkyl, (Ci-C6)hydroxyalkyl, (Ci-C6)halohydroxyalkyl, or (C3-Cvlcarbocyclyl, wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D, (Ci -C6)alkoxy, -SF< -SRua, -NR14R14’, -C(O)NR32R33, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R i
[0552] R9 and Rio are each independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, or (Ci-Ce)haloalkyl;
[0553] Rn is independently at each occurrence H, (Ci-Ce)alkoxy, -NH2, -N(H)(C’i-C)alkyl.
[0554] -N((Ci-C6)alkyl)2, (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (Cs-Cio)aryl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from
[0555] (Ci-Ce)alkyl, (Ci-Ce)alkoxy. (Ci-C6)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2, and -CN: R12 is independently at each occurrence H, (Ci-C6)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci- Ce)haloalkyl, halogen, -OH, -NH2, and -CN, or (C. -C io)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-Cs)alkoxy, (Ci-C6)hydroxyalkyl, (Ci- Ce)haloalkyl, halogen. -OH, -NH2, and -CN:
[0556] Ri2’ is independently at each occurrence H or (Ci-Ce)alkyl; R13 is independently at each occurrence (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;
[0557] Ria- is independently at each occurrence H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;
[0558] R1 and R14 arc each independently at each occurrence H or (Ci-Ce)alkyl;
[0559] Ri4a is H, (Ci-Cs)alkyl or (Ci-Cfi)haloalkyl;Attorney Docket No.: N2109-7025WO
[0560] Ris and Ri5’ are each independently at each occurrence D, (Ci-Cfijalkyl, (Ci-C„)dcutcroalkyl. (Ci-Cejhaloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Cs)hydroxyalkyl, halogen, -OH, -NR30R31, -SF5, -SRie, -CN, -C(O)NR32R33, -C(O)OR32, (C3-C?)carbocyclyl, -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N. NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S), wherein alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NR35R36. -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and R19; or
[0561] two Ris. when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, hctcroaryl. carbocyclyl, and heterocyclyl are optionally substituted with one or more R17;
[0562] two Ris’, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R17; or
[0563] two R15 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; or
[0564] two Ris’ when on the same carbon atom form C=(0);
[0565] Rie is H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;
[0566] R17 is independently at each occurrence D, (Ci-Ce)alkyl, (Ci-Cejdeuteroalkyl, (Ci-Cejhaloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SRis, or -CN;
[0567] Ris is H, (Ci-Ce)alkyl, or (Ci-Ce)haloalkyl;
[0568] each R19 is independently at each occurrence (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, -OR42, -NR2oR2O’, -CN, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (Ce-Cio) aryl, or monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R2; or
[0569] two R19 when on the same carbon atom form C=(0); orAttorney Docket No.: N2109-7025WO
[0570] two R19 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more Ri?:
[0571] R20 and R20 are each independently at each occurrence H or (Ci-Cs)alkyl, wherein the alkyl is optionally substituted with one or more R41;
[0572] each R21 is independently at each occurrence (Ci-Cejalkyl, (Ci-C6)haloalkyl. (Ci-C„)alkoxy. (Ci-Cjhaloalkoxy. (Ci-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or
[0573] two R21, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S. wherein the phenyl and heteroaryl are optionally substituted with one or more R15:
[0574] each R22 is independently at each occurrence (Ci-Cejalkyl, (Ci-C.)haloalkyl. (Ci-Cejalkoxy, (Ci-Cjhaloalkoxy. (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR26, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or
[0575] two R22 together with the atoms to which they are attached form a (C3-C?)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;
[0576] each R23 is independently at each occurrence D, (Ci-Ce)alkyl, (Ci-Cejhaloalkyl, (Ci-Cejalkoxy, (Ci-Cjhaloalkoxy. (Ci-Cgjhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR27, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S; or
[0577] two R23 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;
[0578] each R24 is independently at each occurrence D, (Ci-Ce)alkyl, (Ci-Cejhaloalkyl, (Ci-Cejalkoxy, (Ci-Cejhaloalkoxy, (Ci-C )hydroxyalkyl. halogen, -OH, -NH2, -SF5, -SR28, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;
[0579] R25, R26, R27, R28, and R29 are each independently at each occurrence H. (Ci-Ce)alkyl, or (Ci-Cejhaloalkyl; R30 and R31 are each independently at each occurrence H, (Ci-Cejalkyl, (Ci-C,)haloalkyl. (C3-C7)carbocyclyl, -C(0)Rs4, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17;Attorney Docket No.: N2109-7025WO
[0580] Rso and R31 are each independently at each occurrence H, (Ci-Cb)alkyl, (Ci-C,.)haloalkyl. (C3-C’vicarbocyclyl. -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17;
[0581] R32, R33, and R34 are each independently at each occurrence H or (Ci-Ce)alkyl;
[0582] R35 and R36 are each independently at each occurrence H, (Ci-Cs)alkyl, or -C(O)R39:
[0583] R37. 38. and R39 are each independently at each occurrence H or (Ci-Ce)alkyl;
[0584] R 0 is D, (Ci-Celalkyl, (Ci-Csldeuteroalkyl, (Ci-Cejhaloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR30R31, -SR,. -CN, -C(O)NR32R33, -C(O)OR32, (Cs-C7)carbocyclyl, -O(C3-C7)carbocyclyl, or phenyl;
[0585] each R41 is independently at each occurrence D, halogen, -OH, (C3-C7)carbocyclyl, phenyl, or 5-or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl are optionally substituted with one or more R17;
[0586] each R42 is independently at each occurrence H, (Ci-Cejalkyl, tris[(Ci -Ce)alkyl]silyl, phenyl, or 5-or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein alkyl, phenyl, and heteroaryl are optionally substituted with one or more Ri 7:
[0587] 11 is 0, 1, or 2;
[0588] 0 is 0, 1, or 2;
[0589] p is 0, 1, 2, 3, or 4;
[0590] q is 1, 2, or 3; and
[0591] r is 0 or 1.
[0592] 2. The compound according to embodiment 1, wherein Ri is H.
[0593] 3. The compound according to any one of the preceding embodiments, wherein R2ais H.
[0594] 4. The compound according to any one of the preceding embodiments, wherein R2b is H.
[0595] 5. The compound according to any one of the preceding embodiments, wherein R2Cis H.
[0596] 6. The compound according to any one of the preceding embodiments, wherein R2d is H.
[0597] 7. The compound according to any one of the preceding embodiments, wherein one to four members of Ria, R2b, R2c, and R2d is CH,
[0598] 8. 8. Tire compound of any one of the preceding embodiments, wherein Xi is CR3.
[0599] 9. Tire compound of any one of the preceding embodiments, wherein Xi is N.
[0600] 10. Hie compound of any one of the preceding embodiments, wherein X2is N.Attorney Docket No.: N2109-7025WO
[0601] 11. The compound of any one of the preceding embodiments, wherein X2is CRs.
[0602] 12. The compound of any one of the preceding embodiments, wherein R3is H.
[0603] 13. The compound of any one of the preceding embodiments, wherein R3is D.
[0604] 14. The compound of any one of the preceding embodiments, wherein R3is CH3.
[0605] 15. Tire compound of any one of the preceding embodiments, wherein Ria and Rib are independently in each instance H, (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, -OH, -O-(Ci-C6)alkyl, -NR9R10, or halogen.
[0606] 16. The compound of any one of the preceding embodiments, wherein Ria and Rib are independently in each instance -H, -CH3. -C2H5, -CF3, -OH, -OCH3, -NH2, -NHCH3, or -Cl.
[0607] 17. The compound of any one of the preceding embodiments, wherein R5 is independently in each instance H, (Ci-Ce)alkyl or halogen.
[0608] 18. The compound of any one of the preceding embodiments, wherein Rs is independently in each instance -H, -CH3, or -F.
[0609] 19. Tire compound of any one of the preceding embodiments, wherein Rs is independently in each instance -H, (Ci-Ce)alkyl, (C3-C7)carbocyclyl, -OH, -O-(Ci-C6)alkyl, -NR9R10, or halogen.
[0610] 20. The compound of any one of the preceding embodiments, wherein R5 is independently in each instance -H, -CH3. cyclopropyl, -OH, -OCH3, -NH2, -F, or -Cl.
[0611] 21. The compound of any one of the preceding embodiments, wherein n is 0.
[0612] 22. The compound of any one of the preceding embodiments, wherein n is i.
[0613] 23. The compound of any one of the preceding embodiments, wherein n is 2.
[0614] 24. The compound of any one of the preceding embodiments, wherein at least one of Riaand Rib is H.
[0615] 25. The compound of any one of the preceding embodiments, wherein both of Riaand Rib are H. 26. Tire compound of any one of the preceding embodiments, wherein s is H.
[0616] 27. Tire compound of any one of the preceding embodiments, wherein R7ais H, or (Ci-Ce)alkyl. 28. Hie compound of any one of the preceding embodiments, wherein R7ais -H, -CH3, or -CH(CH3)2.
[0617] 29. The compound of any one of the preceding embodiments, wherein R7b is H.
[0618] 30. The compound of any one of the preceding embodiments, wherein R7cis H.Attorney Docket No.: N2109-7025WO
[0619] 31. The compound of any one of the preceding embodiments, wherein R?d is H.
[0620] 32. The compound of any one of the preceding embodiments, wherein each R7eis independently at each occurrence (Ci-Cs)alkyl, (Ci-C6)deuteroalkyl, halogen, -OH, -O-(Ci-Cs)alkyl, (C3-C7)carbocyclyl, or phenyl wherein the alkyl is optionally substituted with one to six R, and the carbocyclyl is optionally substituted with one to five R22 and the phenyl is optionally substituted with one to five R22; or two R7e, when on the same carbon atom, together with the carbon atom to which they are attached form a (C3-C7)spirocarbocyclyl or 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one to four substituents independently selected from D, (Ci-Cejalkyl, (Ci-Ce)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C. Jalkoxy. (Ci-C. )haloalkoxy. (Ci-C6)hydroxyalkyl, halogen, -C(O)ORB, -C(0)Ri3, and -C(O)NRB RB.
[0621] 33. Tire compound of any one of the preceding embodiments, wherein each R7eis independently at
[0622]
[0623] two R7e, when on the same carbon atom, together with the carbon atom to which they are attached,
[0624]
[0625] Attorney Docket No.: N2109-7025WO
[0626] R in each instance is independently selected from D, (Ci-C6)alkyl, (Ci-CeJdeuteroalkyL (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -C(O)ORir, -C(O)Ris, and -C(O)NR13 R13; and
[0627] RB, R13, R19, R2i, R22, R23, and R2 are defined as in embodiment 1.
[0628] 34. Tire compound of any one of the preceding embodiments, wherein each R?eis independently at
[0629]
[0630] two R?e, when on the same carbon atom, together with the carbon atom to which they are attached.
[0631]
[0632] Attorney Docket No.: N2109-7025WO
[0633] 35. The compound of any one of the preceding embodiments, wherein o is 2.
[0634] 36. The compound of any one of embodiments 1 -34, wherein o is 1.
[0635] 37. The compound of any one of the preceding embodiments, wherein p is 0.
[0636] 38. The compound of any one of embodiments 1-36, wherein p is 1.
[0637] 39. Tire compound of any one of embodiments 1-36, wherein p is 2.
[0638] 40. Tire compound of any one of embodiments 1-36, wherein p is 4.
[0639] 41. Tire compound of any one of the preceding embodiments, having a Formula (la), Formula (lb), Formula (Ic), Formula (le), Formula (If), Formula (Ih), Formula (li), or Formula (Ij):
[0640]
[0641] Attorney Docket No.: N2109-7025WO
[0642]
[0643] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Xi, X2, Ri, Ria, Rib, Ric, Rid, Rda, Rsb. R5, Rs,?a, R?b, R?c, R?d, R?e, Rs, n, o, p, r, and subvariablcs thereof are as defined in embodiment 1.
[0644] 42. The compound of any one of the preceding embodiments, having a Formula (Ik), Formula (Im), Formula (Io), Formula (Ip), Formula (Iq), Formula (Is), Formula (lu), Fonnula (Iw), or Formula (ly):
[0645]
[0646] Attorney Docket No.: N2109-7025WO
[0647]
[0648] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Xi, X2, ta, Rib, R5. R?e, Rs, n, p, and subvariables thereof are as defined in embodiment 1.
[0649] 43. The compound of any one of the preceding embodiments, wherein R8is (Ci-Cs)haloalkyl, (Ci-Ce)hydroxyalkyl, (Ci-C. )alkyl optionally substituted with one to three substituents independently selected from D, (Ci-C6)alkoxy, -SRi4a, -NRuRw, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N. NH, and S, (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N. NH, and S, wherein the phenyl and heteroaryl optionally substituted with one to three Ris and the carbocyclyl and heterocyclyl are optionally substituted with one to three Ri.
[0650] 44. The compound of any one of the preceding embodiments, wherein Rs is selected from:Attorney Docket No.: N2109-7025WO
[0651]
[0652] Xsa is independently selected from 0, S, NH, and NR15:
[0653] R is selected from D, (Ci-C )alkyl and (Ci-Cyicycloalkvl. and is optionally substituted with one or more of D, hydroxy, halogen, alkoxy, imidazol-2-yl, and -CiOlNR^R^: and
[0654] Ris, R32, and R33 are as defined in embodiment 1.
[0655] 45. The compound of any one of the preceding embodiments, wherein Rsis selected from:
[0656]
[0657] Attorney Docket No.: N2109-7025WO
[0658]
[0659] 46. The compound of any one of the preceding embodiments, wherein each R19 is independently at each occurrence (Ci-C6)alkoxy, -NR20R20’, or (Cs-Cy arbocyclyl wherein carbocyclyl is optionally substituted with two to four R23.
[0660] 47. The compound of any one of the preceding embodiments, wherein the compound is selected from any compound provided in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0661] 48. A pharmaceutical composition comprising a compound of any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmaceutically acceptable carrier or excipient.
[0662] 49. Tire pharmaceutical composition according to embodiment 48, further comprising at least one additional pharmaceutical agent.
[0663] 50. The pharmaceutical composition according to embodiment 48, for use in the treatment of a disease or disorder that is affected by the reduction of HIF-ip levels.Attorney Docket No.: N2109-7025WO
[0664] 51. A method of degrading HIF-ip, comprising administering to a patient in need thereof an effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0665] 52. A method of modulating HIF-ip levels comprising administering to a patient in need thereof an effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0666] 53. An in vitro method of reducing the proliferation of a cell, comprising contacting the cell with an effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0667] 54. A method of treating a disease or disorder that is affected by the modulation of HIF-ip levels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0668] 55. Tire method according to embodiment 54, wherein the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary diseases, autoimmune and inflammatory -related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, neovascular diseases, retinal vascular diseases, fibrosis, endometriosis, preeclampsia, and allergic and genetic diseases.
[0669] 56. The method according to embodiment 54, wherein the disease or disorder is selected from renal cell carcinoma (RCC), von Hippel-Lindau disease (VHL), advanced pheochromocytoma / paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), pulmonary arterial hypertension (PAH), glioblastoma, colitis, Crohn’s disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease.
[0670] 57. A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0671] 58. The method according to embodiment 57, wherein the cancer is VHL-deficient cancer.
[0672] 59. The method according to embodiment 57, wherein the cancer is selected from renal cell carcinoma (RCC), glioblastoma, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’sAttorney Docket No.: N2109-7025WO
[0673] lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), and myeloid leukemia.
[0674] 60. A method for reducing HIF-ip levels, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt thereof.
[0675] 61. A method of treating von Hippel-Lindau (VHL) disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0676] 62. A method of treating a neoplastic condition, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0677] 63. A method of treating renal cell carcinoma (RCC), comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
[0678] 64. The method of embodiment 63, wherein the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
[0679] 65. The method according to any one of embodiments 54-64, wherein the administration is oral, parenteral, subcutaneous, by injection, or by infusion.
[0680] 66. A compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder that is affected by the reduction of HIF-ip levels.
[0681] 67. A compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder associated with the reduction of HIF-ip levels.
[0682] 68. Use of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of HIF-ip levels.Attorney Docket No.: N2109-7025WO
[0683] 69. Use of a compound according to any one of the preceding embodiments, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder associated with the reduction of HIF-ip levels.
[0684] 70. The compound for use according to embodiment 68 or 69 or the use according to embodiment 52 or 53, wherein the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases.
[0685] EXAMPLES
[0686] The disclosure is further illustrated by the following examples and synthesis schemes, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure and / or scope of the appended claims.
[0687] Compounds of the present disclosure may be prepared by methods known in the art of organic synthesis. In all of tire methods it is understood that protecting groups for sensitive or reactive groups may be employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1999) Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art.
[0688] Analytical Methods, Materials, and Instrumentation
[0689] Unless otherwise noted, reagents and solvents were used as received from commercial suppliers. Proton nuclear magnetic resonance (NMR) spectra were obtained on either 500 MHz Bruker Avance II, AV-500 spectrometer, 400 MHz Bruker spectrometer, or Varian Oxford 400 MHz spectrometer unless otherwise noted. Spectra are given in ppm (5) and coupling constants, J, are reported in Hertz.
[0690] Tetramethylsilane (TMS) was used where indicated as an internal standard. Chemical shifts are reported in ppm using dimethyl sulfoxide (52.50), methanol (83.31), chloroform (87.26) or other solvent residual protons as an internal reference, as indicated in NMR spectral data. A small amount of the dry sample (2-Attorney Docket No.: N2109-7025WO
[0691] 5 mg) was dissolved in an appropriate deuterated solvent (1 mL). The chemical names were generated using ChemBioDraw Ultra v21 from Cambridge Soft.
[0692] Mass spectra (HESI-MS) w ere collected using a Thermo Scientific UHPLC-MS Vanquish with a LTQ Linear Ion Trap or mass spectra (ESI-MS) were collected using a Waters System (Acquity UPLC and a QDa II Single Quadrupole mass detector) or Agilent- 1290 Infinity II ( 6125 Single Quadrupole); all masses reported are the m / z of the protonated parent ions unless recorded otherwise. The sample was dissolved in a suitable solvent such as MeCN, DMSO, or MeOH and was injected directly into the column using an automated sample handler. The analysis was performed with one of the following methods:
[0693] LCMS Analysis Methods:
[0694] Method A: Column: Phenomenex Kinetex (50 x 3.0 mm, 2.6 pm), eluent A: 0.1% formic acid in water: MeCN (95:5). B: 0.05% Formic acid in MeCN; flow rate: 0.8 mL / min, Run time: 4 min. Gradient (time in minutes, %A): [0.01, 95; 0.25, 95; 2.50. 5; 3.50, 5; 3.60, 95; 4.00. 95],
[0695] Method B: Column: Phenomenex Kinetex (50 x 3.0 mm, 2.6 pm), eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 0.8 mL / min. Run time: 4 min. Gradient (time in minutes, %A): [0.01, 90; 0.25, 90; 2.50, 2; 3.50, 2; 3.60, 90; 4.00, 90],
[0696] Method C: Column: Phenomenex Kinetex EVO C18 (50 x 3.0 mm, 2.6 pm), eluent A: 0.1% Formic acid in water; B: 0.05% Formic acid in Acetonitrile; flow rate: 0.8 mL / min. Run time: 4 min. Gradient (time in minutes. %A): [0.01, 95; 0.25. 95; 2.50, 5; 3.50. 5; 3.60. 95; 4.00, 95],
[0697] Method D: Column: Phenomenex Kinetex (50 x 3.0mm, 2.6pm) eluent A: 0.1% formic acid in water; B: 0.05% formic acid in acetonitrile; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.01, 90; 1.50, 90; 7.00, 2; 8.50, 2; 9.00, 90; 10.00, 90],
[0698] Method E: Column: Phenomenex Kinetex (50 x 3.0 mm, 2.6 pm), eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.01, 90; 1.50, 90; 7.00, 2; 8.50, 2; 9.00, 90; 10.00, 90],
[0699] Method F: Column: Phenomenex Kinetex EVO C18 (50 x 3.0 mm, 2.6pm), eluent A: 0.1% trifluoroacetic acid in water; B: acetonitrile; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.01, 90; 1.50, 90; 7.00, 2; 8.50, 2; 9.00, 90; 10.00, 90],
[0700] Method G: Column: X-Bridgc C8 (50 x 3.5 mm, 4.6pm), eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 1 mL / min. Runtime: 10 min. Gradient (time in minutes, %A): [0.01, 90; 1.50, 90; 7.00. 2; 8.50. 2; 9.00, 90; 10.00, 90],
[0701] Method H: Column: Phenomenex Kinetex EVO C18 (50 x 3.0 mm, 2.6 pm), eluent A: 0.1% formic acid in water; B: 0.05 % formic acid in acetonitrile; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.01, 95; 1.50, 95; 7.00, 2; 8.50, 2; 9.00, 95; 10.00, 95],Attorney Docket No.: N2109-7025WO
[0702] Method I: Column: Acquity C18 (50 x 2.1mm, 1.7pm), eluent A: 0.1% formic acid in water; B: 0.05% Formic acid in Acetonitrile; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.01, 90; 1.50, 90; 7.00, 2; 8.50, 2; 9.00, 90; 10.00, 90],
[0703] Method J: Column: X-Bridge C8 (50 X 3.5 mm, 4.6pm), eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 1.0 mL / min. Rimtime: 4 min. Gradient (time in minutes, %A): [0.01, 90; 0.20, 90: 2.50. 2; 3.50. 2; 3.60, 90: 4.00. 90],
[0704] Method K: Column: Halo ELV C18 (50x3.0mm), 2.7pm, eluent A: 5 mM ammonium
[0705] acetate in water; B: 100% MeCN; flow rate: 0.8 mL / min. Runtime: 10 min. Gradient (time in minutes, %A): [0.00, 90; 1.50, 90; 7.00, 2; 8.50, 2; 9.00, 90; 10.00, 90],
[0706] Method L: Column: Halo ELV C18 (50x3.0mm), 2.7pm, eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 1.0 mL / min. Runtime: 10 min. Gradient (time in minutes, %A): [0.00, 90; 1.50, 90: 7.00. 2; 8.50. 2; 9.00, 90: 10.00, 90],
[0707] Method M: Column: Phenomenex Kinetex (50 x 3.0 mm, 2.6pm), eluent A: 10 mM ammonium acetate in water; B: 100% MeCN; flow rate: 0.8 mL / min. Run time: 10 min. Gradient (time in minutes, %A): [0.00, 98; 1.50, 98; 7.00, 2; 8.50, 2; 9.00, 98; 10.00, 98],
[0708] Method N: Phenomenex Kinetex (50 x 3.0 mm, 2.6 pm). eluent A: 0.1% Formic acid in water: MeCN (95:5). B: 0.05% Formic acid in MeCN; flow rate: 0.7 mL / min, Run time: 3.2 min.
[0709] Gradient (time in minutes, %A): [0.00, 95; 2.00, 0; 2.90, 0; 3.00, 95; 3.20, 95],
[0710] Method O: Zorbax eclipse plus C 18(50 x 2.1 mm, 1,8pm), eluent A: 1 OmM ammonium acetate in water B: 100% acetonitrile; Flow rate: 0.8 mL / min, Run time...
Claims
1. Attorney Docket No.: N2109-7025WOCLAIMSWhat is claimed is:
1. A compound of Formula (I):pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein:Xi is N or CR3;X2is N, N(O), or CR5;Ri is H, D, -C(O)Rn, -CH2OC(O)RH, -CH2OC(O)NHRI2. -CH2OC(O)ORI2, -P(O)(OR]2)2, -CH2OP(O)(ORi2)2, -CH2OP(O)(OH)ORI2. -CH2OP(O)(RI2)2, -CH2OC(O)CH2NHC(O)CH2NH2. -CH2OC(O)CH(R12)NHRI2, -CH2OC(O)(CH2)q-C(O)ORi2, or -CH2OC(O)-(5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S);R2a, R2b, R2c, and R2ciare each independently H, D, (Ci-Ce)alkyl, (C -C. )dcuteroalkyl. halogen, or -OH; ortwo of R2a, R2b, R2C, and R d may be taken together with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl. wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40;Rs is D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, or halogen; or,R3may be taken together with one of R2a, R2b, R2c, and R2d with the carbon atom to which they are attached to form a (C3-C7)carbocyclyl or (C3-C7)spirocarbocyclyl, wherein carbocyclyl and spirocarbocyclyl are each optionally substituted with one or more R40:R4aand Rib are each independently H. D, (Ci-Ce)alkyl, (C2-C,)dcutcroalkyl. (Ci-C6)haloalkyl. (Ci-Ce)alkoxy, (C-C.)deutcroalkoxy. (Ci-C6)haloalkoxy, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4-to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S; halogen, -OH, or -NR9R10; wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40;each R5 is independently H, D, (Ci-Ce)alkyl, (C -C„)dcutcroalkyl. (Ci-C6)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)deuteroalkoxy, (Ci-Cslhaloalkoxy, (C3-C7)carbocyclyl, -O(C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S: halogen, -OH, or -Attorney Docket No.: N2109-7025WONR9R10, wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, deuteroalkoxy, haloalkoxy, carbocyclyl, and heterocyclyl is optionally substituted with one or more R40;Rs is H, D, (Ci-Ce)hydroxyalkyl, (Ci-C6)halohydroxyalkyl, (Ci-C6)aminoalkyl, (Ci-Ce)alkyl-O-(Ci-C6)hydroxyalkyl, -C(O)Rn, -CH2OC(O)Rn, -CH2OC(O)NHRI2, -CH2OC(O)ORI2, -P(O)(ORI2)2, -CH2OP(O)(OH)OR]2, or -CH2OP(O)(R]2)2;R?a, R?b. R?c, and R?a are each independently H, D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl. (Ci-C,.)haloalkyl. (Ci-Ce)alkoxy, (Ci-C6)haloalkoxy, halogen, (Ci-Ce)hydroxyalkyl, -CN, -OH, -O-(Ci-Ce)hydroxyalkyl, (Cs-C 10) aryl, 5- or 6-membered hetcroar l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19, the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22: ortwo of R7a, R?b, R?c, and R?d are taken together with the carbon atom(s) to which they are attached to form (C3-C?)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from D, (Ci-Ce)alkyl, (Ci-C6)deuteroalkyl, (Ci-C6)haloalkyl, (Ci-C„)alkoxy. (C-C.)haloalkoxy. (Ci-Ce)hydroxyalkyl, halogen, -C(0)0Ri3, -C(0)Ri3, and -C(0)NRi3 R13;each R7eis independently at each occurrence D, (C -C’. Jalkyl. (Ci-Cb)deuteroalkyl, (Ci-C )haloalkyl. (Ci-C6)alkoxy, (C -C. Jhaloalkoxy. halogen, (Ci-C6)hydroxyalkyl, -CN, -OH, -O-(Ci-C. )hydroxyalkyl. (C,-C 10) aryl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl is optionally substituted with one or more R19. the aryl and heteroaryl are optionally substituted with one or more R2I, and the carbocyclyl and heterocyclyl are optionally substituted with one or more R22; ortwo R7etogether with the carbon atom(s) to which they are attached form a (C3-C7)carbocyclyl, (C3-C7)spirocarbocyclyl, or a 4- to 7-membered spiroheterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl, spirocarbocyclyl and spiroheterocyclyl are optionally substituted with one or more substituents independently selected from H. D. (Ci-Ce)alkyl, (Ci-C,,)dcutcroalkyl. (Ci-Ce)haloalkyl, (Ci-C6)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -C(O)OR13, -C(O)R13, -C(O)NR13 R13, and oxo; orone R7eis taken together with any one of R7a, R / b, R7c, and R? J and the atoms to which they are attached to fomi a (C3-C7)carbocyclyl or 4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 hctcroatomsAttorney Docket No.: N2109-7025WOselected from O, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R22;Rs is (Ci-Ce)alkyl, (Ci-C. )haloalkyl. (Ci-C6)hydroxyalkyl, (Ci-C6)halohydroxyalkyl, or (C3-Cvjcarbocyclyl. wherein alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, and carbocyclyl are optionally substituted with one or more substituents independently selected from R21, D, (Ci-Ce)alkoxy, -SF5, -SRi4a, -NR14R14’. -C(O)NR32R33. phenyl. 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more R15 and the carbocyclyl and heterocyclyl are optionally substituted with one or more R15;R9 and Rio are each independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-Ce)deuteroalkyl, or (Ci-Ce)haloalkyl;R11 is independently at each occurrence H, (Ci-Ce)alkoxy. -NH2, -N(H)(Ci-Ce)alkyl,-N((Ci-C6)alkyl)2, (Ci-C6)alkyl optionally substituted with one or more substituents independently selected from (Ce-Cio)aryl, (Ci-C6)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C6)haloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from(Ci-C6)alkyl, (Ci-Ce)alkoxy. (Ci-C6)hydroxyalkyl, (Ci-Ce)haloalkyl, halogen, -OH, -NH2, and -CN; R12 is independently at each occurrence H, (Ci-Ce)alkyl optionally substituted with one or more substituents independently selected from (Ce-CiolaryL (Cj-C,. (alkoxy. (Ci-Ce) hydroxyalkyl, (Ci-Celhaloalkyl, halogen, -OH, -NH2, and -CN, or (Ce-Cio)aryl optionally substituted with one or more substituents independently selected from (Ci-Ce)alkyl, (Ci-Ce)alkoxy, (Ci-C6)hydroxyalkyl, (Ci-C.)haloalkyl. halogen, -OH, -NH2, and -CN;Ri2’ is independently at each occurrence H or (Ci-Ce)alkyl; R13 is independently at each occurrence (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;R13- is independently at each occurrence H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;R14 and R. are each independently at each occurrence H or (Ci-Ce)alkyl;Ri4a is H, (Ci-Ce)alkyl or (Ci-Cfi)haloalkyl;Ris and Ris are each independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-C. )deutcroalkyl. (Ci-C )haloalkyl. (Ci-Cs)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxy alkyl, halogen, -OH, -NR30R31, -SF5, -SR16, -CN. -C(O)NR32R33. -C(O)OR32, (C3-C7)carbocyclyl. -O(C3-C7)carbocyclyl, phenyl, -O-phenyl, monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, -O-(monocyclic or bicyclic 5- to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S or -0-(4- to 7-mcmbcrcd heterocyclyl comprising 1 to 4 hctcroatoms selected from 0, N, NH, and S), wherein each alkyl, deuteroalkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl,Attorney Docket No.: N2109-7025WOheteroaryl, carbocyclyl, and heterocyclyl are optionally substituted with one or more substituents selected from (Ci-Cejalkyl. (Ci-Cejhaloalkyl, (Ci-C )alkoxy. (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR35R36, -C(O)NR37R38, -C(O)R37, -C(O)OR37, -SF5, -SR29, SO2NR30R31, -CN, and RI9; ortwo R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the phenyl, heteroaryl, carbocyclyL and heterocyclyl are optionally substituted with one or more R, 7:two R15, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl are optionally substituted with one or more RI7: ortwo Ri5’ together with the atoms to which they are attached fonn a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17; ortwo Ris when on the same carbon atom fonn C=(0);Ri6 is H, (Ci-Ce)alkyl or (Ci-Ce)haloalkyl;R17 is independently at each occurrence H, D, (Ci-C )alkyl. (Ci-Cgjdeuteroalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (C-C,)hydroxyalk l. halogen, -OH, -NR14R14, -NH2, -SF5, -SRis, or -CN; ortwo R17 when on the same carbon atom form C=(0);Ris is H, (Ci-Cejalkyl, or (Ci-Ce)haloalkyl;each R19 is independently at each occurrence H, (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, -OR42, -NR20R20, -OC(O)OR42. -OC(0)NR2oR2o, -CN, (C3-C7)carbocyclyl, 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (Ce-Cio) aryl, or monocyclic or bicyclic 5-to 10-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R23 and the aryl and heteroaryl are optionally substituted with one or more R24; ortwo R19 when on the same carbon atom form C=(0); ortwo R19 together with the atoms to which they are attached form a (C3-C7)carbocyclyl or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0. N, NH, and S, wherein the carbocyclyl and heterocyclyl are optionally substituted with one or more R17;R20 and R20 are each independently at each occurrence H, (Ci-Ce)alkyl, or (Ce-Cio)aryl, wherein the alkyl and aryl arc each optionally substituted with one or more R 1;Attorney Docket No.: N2109-7025WOeach R21 is independently at each occurrence (Ci-Cejalkyl, (Cr-CejhaloalkyL (Ci-Ce)alkoxy, (Ci-Cejhaloalkoxy, (Ci-C6)hydroxyalkyl, halogen, -OH, -NH2, -SFs, -SR25, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C?)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17: ortwo R21, when on adjacent atoms, together with the atoms to which they are attached form a phenyl or 5- or 6-membered hetcroar l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and hetcroaryl are optionally substituted with one or more R15;each R22 is independently at each occurrence (Ci-Cejalkyl, (Ci-Cejhaloalkyl, (Ci-Ce)alkoxy, (Ci-C.jhaloalkoxy. (Ci-Cgjhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR26, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C’s-CNcarbocycIvl. or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S: ortwo R22together with the atoms to which they are attached form a (Cs-Cyjcarbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R23 is independently at each occurrence H, D, (Cr-Cgjalkyl, (Ci-Ce)haloalkyl, (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen. -OH, -NH2. -SF5, -SR27, -CN. phenyl. 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17; ortwo R23 together with the atoms to which they are attached fonn a (C3-C7)carbocyclyl or a 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S;each R24 is independently at each occurrence H, D, (Ci-Ce)alkyl, (Ci-Ce)haloalkyl, (Ci-C )alkoxy. (Ci-Ce)haloalkoxy, (Ci-Cejhydroxyalkyl, halogen, -OH, -NH2, -SF5, -SR28, -CN, phenyl, 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, (C3-C7)carbocyclyl, or 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, wherein the alkyl, haloalkyl, alkoxy, haloalkoxy, hydroxyalkyl, phenyl, heteroaryl, carbocyclyl, and heterocyclyl are each optionally substituted with one or more R17;R25, R26, R27, R28, and R29 are each independently at each occurrence H, (Ci-Ce)alkyl, or (Cr-Cejhaloalkyl; R30 and R31 are each independently at each occurrence H, (Ci-Cejalkyl, (Ci-Cejhaloalkyl, (C3-C7)carbocyclyl, -C(O)R34, phenyl, or 5- or 6-membered hetcroary l comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or hetcroary l can be substituted with one or more R17;Attorney Docket No.: N2109-7025WORso and R31 are each independently at each occurrence H, (Ci-COalkyl. (Ci-C,.)haloalkyl. (C3-C’vicarbocyclyl. -C(O)R34, phenyl, or 5- or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl can be substituted with one or more R17;R32, R33, and R34 are each independently at each occurrence H or (Ci-Ce)alkyl;R35 and R36 are each independently at each occurrence H, (Ci-Cs)alkyl, or -C(O)R39:R37.
38. and R39 are each independently at each occurrence H or (Ci-Ce)alkyl;R 0 is D, (Ci-Celalkyl, (Ci-Csldeuteroalkyl, (Ci-CeJhaloalkyL (Ci-Ce)alkoxy, (Ci-Ce)haloalkoxy, (Ci-Ce)hydroxyalkyl, halogen, -OH, -NR30R31, -SR,. -CN, -C(O)NR32R33, -C(O)OR32, (Cs-C7)carbocyclyl, -O(C3-C7)carbocyclyl, or phenyl;each R41 is independently at each occurrence D, halogen, -OH, (C3-C7)carbocyclyl, phenyl, or 5-or 6-membered heteroaryl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl or heteroaryl are optionally substituted with one or more R17;each R42 is independently at each occurrence H, (Ci-Celalkyl, Si((Ci-C6)alkyl)3, -(CH2)o-2-(C3-C7)carbocyclyl, -(CH2)0.2-(4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), -(CH2)0.2-(phenyl), or -(CH2)0-2-(5- or 6-membered hcteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S), wherein each alkyl, carbocyclyl, heterocyclyl, phenyl, and heteroaryl is optionally substituted with one or more R17;n is 0, 1, or 2:o is 0, 1, or 2;p is 0, 1, 2, 3, or 4;q is 1, 2, or 3; andr is 0 or 1.
2. The compound according to claim 1, wherein Ri is H.
3. The compound according to claim 1, wherein R2ais H.
4. The compound according to claim 1, wherein R2b is H.
5. The compound according to claim 1, wherein R2cis H.
6. The compound according to claim 1, wherein R2d is H.
7. The compound according to claim 1, wherein Xi is CR3.Attorney Docket No.: N2109-7025WO8. The compound according to claim 1, wherein X2is CR5.
9. The compound according to claim 1, wherein R3 is H.
10. The compound according to claim 1, wherein +aand R+n are independently in each instance H or (Ci-C6)alkyl.
11. The compound according to claim 1, wherein R4a and R* are independently in each instance -H or -CH3.
12. The compound according to claim 1, wherein at least one of R+, and R* is H.
13. The compound according to claim 1, wherein both of R7aand R®, are H.
14. The compound according to claim 1, wherein R5 is independently in each instance H or halogen.
15. The compound according to claim 1, wherein R5 is independently in each instance -H or -F.
16. The compound according to claim 1, wherein n is 0.
17. The compound according to claim 1, wherein R, is H or (Ci-C6)hydroxyalkyl.
18. The compound according to claim 1, wherein Rs is H or -CH2CH2OH.
19. The compound according to claim 1, wherein R7ais H.
20. The compound according to claim 1, wherein R?b is H.
21. The compound according to claim 1, wherein R7cis H.
22. The compound according to claim 1, wherein R7d is H.Attorney Docket No.: N2109-7025WO23. The compound according to claim 1, wherein each R7eis independently at each occurrence (Ci-Celalkyl, wherein the alkyl is optionally substituted with one to six R,24. Tire compound according to claim 1, wherein each R7eis independently at each occurrence. wherein R19 and R24 are defined as in claim 1.
25. The compound according to claim 1, wherein each R7eis independently at each occurrence26. The compound according to claim 1, wherein o is 1.
27. The compound according to claim 1, wherein p is 0.
28. Tire compound according to claim 1, wherein p is 1.
29. The compound according to claim 1, having a Fonnula (la). Fonnula (laa), Formula (lb), Formula (Ibb), Formula (Ic), Formula (le), Formula (If), Formula (Ih), Formula (li), or Fonnula (Ij):Attorney Docket No.: N2109-7025WOor a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Xi, X2, Ri, R2a,2b, R2C, RM, U, Rib, Rs, R, R?a, RM, R?c, R?d, R?e, Rs, n, o, p, r, and subvariables thereof are as defined in claim 1.
30. The compound according to claim 1, having a Formula (Ik), Formula (Im), Formula (Io), Formula (Ip), Formula (Iq), Formula (Is), Formula (lu), Formula (Iw), or Formula (ly):Attorney Docket No.: N2109-7025WOor a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Xi, X2, Ra, Rib, R5, R?e, Rs, n, p, and subvariables thereof are as defined in claim 1.
31. The compound according to claim 1, wherein Rs is (Ci -C.,)alkyl optionally substituted with one to three substituents independently selected from D, (C’i-C.)alkoxy. -SRua, -NR14R1, phenyl, 5- or 6-Attorney Docket No.: N2109-7025WOmembered heteroaryl comprising 1 to 4 heteroatoms selected from O, N, NH, and S, (C3-C7)carbocyclyl, and 4- to 7-membered heterocyclyl comprising 1 to 4 heteroatoms selected from 0, N, NH, and S, wherein the phenyl and heteroaryl optionally substituted with one to three R15 and the carbocyclyl and heterocyclyl are optionally substituted with one to three R15.
32. The compound according to claim 1, wherein Rs is selected from:defined in claim 1.
33. Tire compound according to claim 1, wherein R« is34. The compound according to claim 1, wherein the compound is selected from any compound provided in Table 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
35. A pharmaceutical composition comprising a compound of claim 1, or a pharmacally acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, and a pharmacally acceptable carrier or excipient.
36. The pharmaceutical composition according to claim 35, further comprising at least one additional pharmaceutical agent.
37. The pharmaceutical composition according to claim 35, for use in the treatment of a disease or disorder that is affected by the reduction of HIF-ip levels.
38. A method of degrading HIF-ip, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodnig. stereoisomer, or tautomer thereof.
39. A method of modulating HIF-ip levels comprising administering to a patient in need thereof an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.Attorney Docket No.: N2109-7025WO40. An in vitro method of reducing the proliferation of a cell, comprising contacting the cell with an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
41. A method of treating a disease or disorder that is affected by the modulation of HIF-ip levels, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
42. The method according to claim 41, wherein the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary diseases, autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, neovascular diseases, retinal vascular diseases, fibrosis, endometriosis, preeclampsia, and allergic and genetic diseases.
43. The method according to claim 41, wherein the disease or disorder is selected from renal cell carcinoma (RCC), von Hippel-Lindau disease (VHL), advanced pheochromocytoma / paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), pulmonary arterial hypertension (PAH), glioblastoma, colitis, Crohn's disease, ulcerative colitis, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngeal cancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), myeloid leukemia, and coronary heart disease.
44. A method of treating cancer, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
45. The method according to claim 44, wherein the cancer is VHL-deficient cancer.
46. The method according to claim 44, wherein the cancer is selected from renal cell carcinoma (RCC), glioblastoma, T cell leukemia or T cell lymphoma, Hodgkin’s lymphoma or non-Hodgkin’s lymphoma, non-small cell lung cancer (NSCLC), melanoma, triple -negative breast cancer (TNBC), nasopharyngealAttorney Docket No.: N2109-7025WOcancer (NPC), microsatellite stable colorectal cancer (mssCRC), thymoma, carcinoid, gastrointestinal stromal tumor (GIST), and myeloid leukemia.
47. A method for reducing HIF-ip levels, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.
48. A method of treating von Hippel-Lindau (VHL) disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
49. A method of treating a neoplastic condition, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
50. A method of treating renal cell carcinoma (RCC), comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
51. Tire method of claim 50, wherein the renal cell carcinoma is clear cell renal cell carcinoma (ccRCC).
52. The method according to claim 50, wherein the administration is oral, parenteral, subcutaneous, by injection, or by infusion.
53. A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in the treatment of a disease or disorder that is affected by the reduction ofHIF-ip levels.
54. A compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, for use in treating a disease or disorder associated with the reduction of HIF-ip levels.Attorney Docket No.: N2109-7025WO55. Use of a compound according to claim 1, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the manufacture of a medicament for treating a disease or disorder that is affected by the reduction of HIF-ip levels.
56. Use of a compound according to claim 1. or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, in the treatment of a disease or disorder associated with the reduction ofHIF-ip levels.
57. The compound for use according to claim 53 or 54 or the use according to claim 55 or 56, wherein the disease or disorder is selected from cancer, von Hippel-Lindau (VHL) disease, iron overload disorders, cardiovascular diseases, pulmonary arterial hypertension (PAH), autoimmune and inflammatory-related diseases and conditions, neurodegenerative diseases, viral diseases, metabolic diseases, and allergic and genetic diseases.
